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 ABSTRACT 
The main aim of this thesis was to improve the knowledge of the peripheral mechanisms that 
may participate in the underlying pathophysiology of chronic temporomandibular disorders 
(TMD) myalgia i.e. pain that is experienced locally in the jaw muscles and has myofascial 
trigger points. The project examined the effect of the 5-hydroxytryptamine type 3 (5-HT3)-
antagonist granisetron on experimentally induced muscle pain and whether specific genetic 
variants i.e. polymorphisms (SNPs) in the serotonergic system influences pain perception and 
the pain reducing effect of granisetron. The project also investigated the relationship between 
certain biomarkers; serotonin (5-HT), glutamate, metabolites and pro- and anti-inflammatory 
cytokines in jaw muscle pain.  
 
One part examined the 5-HT3- receptor antagonist granisetron, and its effect on 
experimentally induced masseter muscle pain in healthy participants. Also, whether certain 
polymorphisms in the serotonergic system are involved and may influence the pain response 
and the efficacy of granisetron. The SNPs (rs1062613, rs1176744) in the HTR3A/B genes 
were therefore investigated. 0.5 mL granisetron (Kytril® 1 mg/ml) or placebo (isotonic 
saline, 9 mg/mL) was injected in the masseter muscles in a randomized, placebo-controlled 
and double-blinded order, followed by a bilateral painful injection of either: a) acidic saline 
(0.5 mL, 9 mg/mL, pH 3.3) or b) hypertonic saline (HS, 0.2 mL, 58.5 mg/mL). The pain 
variables; pain intensity, pain duration, pain area and pain pressure threshold (PPT) were 
assessed.  
 
Another part in this project, used a microdialysis technique in order to investigate the 
intramuscular levels of several biomarkers in the masseter muscle, at rest and after 
experimentally induced muscle pain. HS injections and static tooth-clenching were used as 
experimental pain models in healthy, pain-free participants and in patients with TMD 
myalgia. The biomarkers and metabolites analyzed were; 5-HT, glutamate, lactate, pyruvate, 
glucose, glycerol as well as the pro- and anti-inflammatory cytokines; IL-1β, IL-2, IL-4, IL-5, 
IL-6, IL-7 IL-8, IL-10, IL-12, IL-13, TNF, IFN- γ and GM-CSF.  
 
The results showed that granisetron had a pain reducing effect on experimentally induced 
masseter muscle pain, both by acidic saline and HS injections. The pain intensity, pain 
duration and pain area were significantly lower on the side pre-treated with granisetron, but 
did not have any effect on the PPT. Also, there were sex differences in pain variables and in 
response to granisetron. The 5-HT3 polymorphisms did not influence any pain variables in 
general or the pain reducing effect of granisetron. However, there were sex differences in 
regards to pain variables and the efficacy of granisetron. Women had higher pain intensity 
and larger pain area after experimentally induced masseter muscle pain, and less pain 
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reduction (pain intensity, duration and area) of granisetron in specific genotypes of the 5-HT3 
polymorphisms. 
 
Intramuscular microdialysis in the masseter muscles of healthy participants showed increased 
levels of 5-HT, glutamate and glycerol after evoked muscle pain with a HS injection, and 5-
HT correlated positively to pain. In TMD myalgia patients, there were higher levels of the 
pro- and anti-inflammatory cytokines IL-6, IL-7, IL-8 and IL-13, throughout the 
microdialysis compared to healthy controls. The cytokines IL-6, IL-7, IL-8, IL-13 and TNF 
increased in response to experimental tooth-clenching in patients, and IL-6 and IL-8 
increased in healthy controls. TMD myalgia patients reported higher pain and fatigue after 
tooth-clenching compared to controls. However, no correlation between the cytokine levels 
and pain and fatigue were found.  
 
In conclusion, the results of this thesis showed that granisetron had a pain reducing effect on 
experimentally evoked masseter muscle pain, with a generally better effect in men. None of 
the 5-HT3 polymorphisms investigated in this thesis, seemed to influence the experimentally 
induced muscle pain or the positive effect of granisetron. Nevertheless, there were some 
indications of gene-to-sex interactions in pain variables and granisetron effects. Therefore, 
one cannot completely exclude the possibility that polymorphisms in the serotonergic system 
may influence, predict or be a risk factor in developing chronic muscle pain. Further research 
is needed to systematically investigate multiple 5-HT polymorphisms in order to draw any 
further conclusions.  
 
Further, the levels of the biomarkers 5-HT, glutamate and glycerol, increased after 
experimentally induced muscle pain in the masseter muscles, but without any sex differences. 
In addition, patients with TMD myalgia constantly had elevated levels of the pro- and anti-
inflammatory cytokines IL-6, IL-7, IL-8 and IL-13 compared to healthy controls. The 
cytokine levels of IL-6, IL-7, IL-8, IL-13 and TNF increased in patients after tooth-clenching, 
and IL-6 and IL-8 increased in controls. This indicates that muscle inflammation could be 
involved in the multifactorial pathophysiology of chronic muscle pain. However, no 
correlations between the cytokine levels and pain and fatigue were found, indicating that 
there is no direct cause-relation effect between increased pain and cytokine release. Other 
peripheral mediators and mechanisms, such as central sensitization can therefore not be ruled 
out in the pathophysiology of chronic TMD myalgia. 
 
Key words 
5-HT, Biomarkers, Bruxism, Cytokines, Genetic, Granisetron, Hypertonic saline, Masseter 
muscle, Muscle pain, Myalgia, Pain, Pain threshold, Polymorphism, Temporomandibular 
disorders (TMD).  
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INTRODUCTION 
 
What is pain? Throughout history, man has tried to define and describe pain. The ancient 
Greeks considered pain to be an emotional experience and was often viewed as an external 
punishment. Already in the 600 BC in Egypt, the historian and Bible writer Jeremiah, 
described pain as coming from deep within the intestines and associated pain with strong 
emotions. He asked: “why is my pain chronic and my wound incurable?” 
 
Pain is a word that evokes various associations and emotions depending on experiences. It 
is always subjective and causes both physical and emotional harm, affected by 
psychological factors, with feelings of disappointment, unhappiness, guilt, anxiety and 
depression (Kelley and Clifford, 1997). The modern definition of pain is “an unpleasant 
sensory and emotional experience associated with actual or potential tissue damage, or 
described in terms of such damage” (International Association for the Study of Pain) 
(Merskey and Bogduk, 1994). 
 
Nearly 20 % of the European population suffer from chronic pain (Breivik et al., 2006). 
The most common pain conditions in the orofacial area are temporomandibular disorders 
(TMD), with a prevalence of approximately 10-15 % in the adult population (Isong et al., 
2008; LeResche, 1997) and are twice as common in women as in men (Dao and LeResche, 
2000; Von Korff et al., 1988). TMD are chronic pain conditions localized to the jaw 
muscles and/ or temporomandibular joints and includes symptoms like, restricted mouth 
opening, pain upon chewing, muscle soreness, pain referral and headache (Lund et al., 
2001; Sessle, 1999) leading to a decreased quality of life (Hallberg and Carlsson, 2000; 
Thomas, 2000). In addition to individual suffering, it is a big problem for the society, with 
increased work absence and health care costs (Von Korff et al., 1990; Yokoyama et al., 
2007).  
 
TMD are thought to be triggered by several risk factors such as psychosocial, autonomic 
and genetic factors (Fillingim et al., 2011). The most common subtype is myalgia with pain 
locally in the jaw muscles with myofascial trigger points (Gerwin, 2001). One risk factor 
suggested to contribute to TMD myalgia is tooth-clenching/ grinding (bruxism), leading to 
an overload with decreased blood flow and ischemia causing a release of algesic substances 
and thereby cause pain (Mense, 1993, 2003). Serotonin (5-HT) as an example, is reported 
to be higher in patients with chronic myalgia than in healthy controls (Ernberg et al., 1999; 
Rosendal et al., 2004b). Also central mechanisms are thought to contribute to bruxism by 
disturbances in the dopaminergic system (Lobbezoo and Naeije, 2001). However, the 
knowledge is limited behind the peripheral and central mechanisms of chronic 
musculoskeletal pain. 
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The pathophysiological mechanisms that underlie chronic myalgia and why it is more 
prevalent in women is still not understood. Increased knowledge behind chronic muscle 
pain conditions will help to improve the diagnosis, and may lead to new therapies. This in 
turn may eventually lead to a reduced need of health care resources and health care costs 
and, not least, less suffering for the individual.  
 
Classification of pain  
 
Pain is a defense mechanism providing the body necessary information when potential or 
actual injury occurs (Dubin and Patapoutian, 2010). Pain can be classified by the duration 
i.e. acute or chronic pain (Treede et al., 2015). Since chronic pain consists of various pain 
conditions, a clarification of the concept and classification of chronic pain was recently 
published by IASP (Treede et al., 2015). A compilation of various chronic pain conditions 
was done including; chronic primary pain, chronic cancer pain, chronic postsurgical and 
posttraumatic pain, chronic neuropathic pain, chronic headache and orofacial pain, chronic 
visceral pain and chronic musculoskeletal pain (Treede et al., 2015). In this classification 
TMD pain categorizes under the subgroup of chronic headache and orofacial pain.  
 
Acute pain  
 
Acute pain is a type of pain that begins suddenly, has a short duration and a distinct and 
sharp character. It alerts and warns of disease or threat to the body. The normal healing 
time is within a few weeks (Treede et al., 2015). Acute pain can be caused by many various 
circumstances such as; surgery, broken bones, burns or cuts or labor and childbirth. If acute 
pain is not treated, it may lead to chronic pain. 
 
Chronic pain  
 
Chronic pain is an on-going pain that persists and lasts longer than 3 months, despite the 
fact that the underlying damage has healed. The etiology is unclear, but it might have 
originated with an initial trauma or injury leading to an activation of the acute warning 
system with pain signals that remains active in the nervous system. The severity of pain can 
be classified on pain intensity, pain-related distress and functional impairment. (Treede et 
al., 2015).  
 
Chronic headache and orofacial pain 
 
The definition of chronic headache and orofacial pain is headaches or orofacial pains that 
occur on at least 50 % of the days during at least 3 months (Headache Classification 
Committee of the International Headache, 2013; Treede et al., 2015). TMD are the most 
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common chronic orofacial pain conditions and have a nociceptive and neuropathic 
character (Benoliel et al., 2012; Schiffman et al., 2014). Other orofacial pain conditions 
included in this subcategory are; post-traumatic trigeminal neuropathic pain, persistent 
idiopathic pain and burning mouth syndrome. However, several of these pain conditions are 
cross-referenced to primary chronic pain and chronic neuropathic pain (Treede et al., 2015). 
 
Pathways of orofacial pain 
 
In the orofacial region, pain is mediated by inputs from the fifth cranial nerve (V) called the 
trigeminal nerve. It contains three branches that innervates the craniofacial tissues; The 
Ophthalmic (V1), the Maxillary (V2), and the Mandibular (V3) nerves. When a painful 
stimuli occurs, nociceptors i.e. sensory neurons (nerve cells) are activated, transforming the 
stimuli into electrical signals. The signals are passed on via the primary afferent neurons in 
the trigeminal nerve through the gasserian ganglion, to terminate in the subnucleus 
caudalis, which is considered to be the main site of dispatch information from the 
craniofacial region. In the subnucleus caudalis, the first order neurons synapse on the 
second order neuron and transmits the information through the neospinothalamic tract or 
paleospinothalamic tract to the thalamus. In the thalamus, it synapses on the third order 
neurons before it reaches the cerebral cortex, where pain is experienced (Sarnat and Laskin, 
1992). 
 
There are two different types of axons transmitting pain, A-delta and C-fibers (Dubin and 
Patapoutian, 2010). A-delta fibers are myelinated and transform the signals rapidly with a 
low threshold for pain leading to acute and sharp pain, and terminates in the ventral 
posteromedial nucleus. They respond to mechanical and thermal stimuli. C-fibers are 
unmyelinated and respond to chemical, mechanical and thermal stimuli and terminates in 
the intralaminar nuclei. They have a high threshold for pain leading to slow and burning 
pain. The stimulus (thermal, mechanical, or chemical) gets transduced into electrical 
impulses by proteins in the membrane of these nociceptors, which in turn are transmitted 
along the peripheral and central axon of the nociceptor into the central nervous system 
(CNS) where the signals gets interpreted (Dubin and Patapoutian, 2010). 
 
Biomarkers 
 
For many years, the definition of a biomarker has been discussed. According to one review 
of the literature regarding this matter, they have come to the conclusion that a biomarker is 
something that can be measured and evaluated and is involved in biological processes such 
as pain, inflammation, pharmacological response as well as therapeutic intervention 
(Ptolemy and Rifai, 2010). 
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When a tissue damage or invasion of pathogens occurs, an inflammatory process starts, 
which is a cascade of complex series of immune reactions. The inflammatory process is 
initiated to establish healing and repair. In the clinic, inflammation is characterized by the 
five classical cardinal symptoms; rubor (redness), calor (increased heat), tumor (swelling), 
dolor (pain), and functio laesa (loss of function). The first reaction of an acute inflammation 
is the release of vasodilators and chemotactic factors like histamine, which leads to 
increased permeability and blood flow at the injured site. This is followed by migration of 
phagocytes and serum proteins through the cell walls which destroy bacteria. Several 
inflammatory biomarkers and mediators such as; cytokines, 5-HT, substance P (SP) and 
bradykinin activates the peripheral nociceptors either direct or indirect and cause pain 
(Dray, 1995). 
 
Cytokines 
 
Cytokines are small proteins involved in the immune system. Cytokine means “cell 
movement” and is a generic name including; lymphokines, monokines, chemokines, and 
interleukins (IL). Cytokines are produced in muscle cells, immune cells (T-cells, B-cells 
and macrophages) and other cells like fibroblasts and endothelial cells. There are both pro- 
and anti-inflammatory cytokines and they are often released in a cascade in response to 
tissue damage (Zhang and An, 2007). The pro-inflammatory cytokines for example 
stimulate its target cell to produce and release other cytokines initiating the inflammation, 
while anti-inflammatory cytokines control the pro-inflammatory cytokine response (Zhang 
and An, 2007).  
 
The pro- and anti-inflammatory cytokines interact with each other in a balanced matter, in 
order to fight an infection and promote proper wound healing. A possible peripheral factor 
in chronic muscle pain conditions may be an imbalance between pro- and anti-
inflammatory cytokines, promoting or maintaining pain (Figure 1). Previous studies have 
showed that pro-inflammatory cytokines seem to be involved in chronic pain conditions 
(Koch et al., 2007) while anti-inflammatory cytokines have an analgesic effect (Uceyler et 
al., 2006). 
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Figure 1. Illustration of the balance between pro- and anti-inflammatory cytokines. In a 
normal healthy condition, the pro- and anti-inflammatory cytokines interact with each 
other in a balanced matter promoting a stable environment (to the left). If an imbalance 
between pro- and anti-inflammatory cytokines occurs (to the right), an inflammatory 
response is triggered, which may play an important role in induction and maintenance of 
chronic pain. 
 
 
The major anti-inflammatory cytokines are; IL-4, IL-6, IL-10, IL-11, and IL-13 (Opal and 
DePalo, 2000). IL-4 is produced by T cells, mast cells, B cells and stromal cells and can 
inhibit and down-regulate the effect of pro-inflammatory cytokines such as; tumor necrosis 
factor (TNF), IL-1β, IL-6, IL-8 and nitric oxide production (Opal and DePalo, 2000). IL-6 
acts both as a pro- and anti-inflammatory cytokine, involved in nociception, hyperalgesia 
and sickness response (McMahon et al., 2005; Sommer and Kress, 2004; Watkins and 
Maier, 2005). IL-6 can control the levels of pro-inflammatory cytokines (Xing et al., 1998) 
either by promoting or inhibiting the production. For example, IL-6 can inhibit the 
production of the cytokines Granulocyte-macrophage colony-stimulating factor (GM-CSF), 
Interferon (IFN)-γ and also some key inflammatory responses by blocking the synthesis of 
TNF and IL-1 (Barton, 1997). Previous studies have shown that the levels of IL-6 are 
increased in patients with whiplash-associated trapezius myalgia (Gerdle et al., 2008b) and 
also in subjects with myofascial trigger points in the trapezius muscle compared to controls 
(Shah et al., 2008; Shah et al., 2005).  
 
Further, IL-10 together with IL-4 are known for inhibiting the cytokines IL-2, TNF and 
IFN-γ (Opal and DePalo, 2000; Zhang and An, 2007). A previous study showed that 
patients with chronic widespread pain had low blood levels of the anti-inflammatory 
cytokines IL-4 and IL-10, suggesting that the lack of anti-inflammatory cytokines may play 
a role in the pathogenesis of chronic widespread pain conditions (Uceyler et al., 2006). 
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Another anti-inflammatory cytokine is IL-13, which is mainly produced by T cells and can 
inhibit the expression of nitric oxide and the pro-inflammatory cytokines IL-1, IL-6, IL-8, 
IL-10 and IL-12 (Lin et al., 2000). Together with IL-4, they share a common cellular 
receptor (IL-4 type 1 receptor) and also similar functions (Lin et al., 2000). 
 
Pro-inflammatory cytokines are mainly produced by macrophages and are thought to be 
involved in the pathophysiology of chronic pain conditions since these cytokines 
contributes to an up-regulation of the immune system by initiating the inflammatory 
cascade (Zhang and An, 2007). A previous study showed that patients with chronic pain 
conditions such as; neuropathic, nociceptive and mixed pain, had higher levels of the pro-
inflammatory cytokines IL-1β, TNF, IL-2, IL-6 and IFN- γ in plasma, compared to healthy 
controls and that the increased levels correlated to pain intensity (Koch et al., 2007). 
 
Further, in neuronal and glial cells, injections of IL-1β in rats and rabbits increased the 
production of SP and prostaglandins (Jeanjean et al., 1995; Schweizer et al., 1988), which 
are well-known inflammatory mediators triggering nociceptors indirectly and therefore 
cause pain (Mense, 1993; Wall and Melzack, 1994). It has also been shown that IL-1β 
directly sensitizes and activates nociceptors in primary afferent neurons (Binshtok et al., 
2008). In muscle diseases such as inflammatory myopathies, IL-1β together with TNF seem 
to be up-regulated (Kuru et al., 2000; Lundberg, 2000). TNF acts via the TNF receptors 1 
and 2 (TNFR1 and TNFR2) (Zhang and An, 2007) and seems to play an important role in 
the inflammatory cascade and immune response by regulating the production of other pro-
inflammatory cytokines, fibroblasts and up-regulation of receptors. For example, TNF can 
promote the production of IL-6 (Sommer and Kress, 2004). Moreover, intramuscular 
injections of TNF and IL-6 respectively in the gastrocnemius muscle of rats induced a long-
lasting hyperalgesia (Dina et al., 2008; Schafers et al., 2003). Also, previous study showed 
an association with higher levels of TNF and depression in healthy men (Suarez et al., 
2002).  
 
Another pro-inflammatory cytokine involved in the inflammatory response is IL-7. It has 
been shown to be elevated in some inflammatory disorders such as; rheumatoid arthritis, 
but also stable and unstable angina (Damas et al., 2003; Harada et al., 1999). Further, IL-8 
is a chemo attractant and activates neutrophils at the site of inflammation (Bickel, 1993). 
Previous studies report higher levels of IL-8 in plasma and cerebrospinal fluid of patients 
with TMD and widespread palpation tenderness and fibromyalgia compared to controls 
(Gur et al., 2002; Kadetoff et al., 2012; Kosek et al., 2015; Slade et al., 2011b). 
Furthermore, GM-CSF contributes to a normal inflammatory cytokine response by its 
recruitment of leukocytes (Lin et al., 2000). Also, it has been shown that GM-CFS delays 
the apoptosis of macrophages and neutrophils (Fanning et al., 1999). In a previous study, 
injections of GM-CFS caused inflammatory pain in mice (Cook et al., 2013). 
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With this in mind, cytokines are undoubtedly important in the progress and maintenance of 
neuropathic and inflammatory pain, thus their role in chronic myalgia are of great interest.  
 
Glutamate and metabolic mediators 
 
Glutamate is one of the body’s twenty amino acids and is found in every part of the body 
and acts as a neurotransmitter by targeting its receptors; N-methyl-D-aspartate receptor 
(NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA). 
When glutamate binds to its receptors in the peripheral nervous system (PNS), peripheral 
sensory afferents are activated and pain is induced (Ren and Dubner, 2010). Several studies 
have shown increased interstitial levels of glutamate in patients with TMD myalgia and 
trapezius myalgia compared to healthy controls, but also that glutamate correlated 
positively to pain (Castrillon et al., 2010; Rosendal et al., 2004b). Furthermore, 
intramuscular injections of glutamate evoked pain (Svensson et al., 2005). Also, painful 
injections in the biceps muscle with hypertonic saline (HS) caused a release of glutamate 
(Tegeder et al., 2002). 
 
Further, the metabolic mediators lactate and pyruvate participate in the final steps of the 
glycolysis (Essen and Kaijser, 1978), hence they are important in the metabolic pathway. 
The concentration of lactate may increase rapidly during intense physical exercise, but the 
increase is rapidly passing (Essen and Kaijser, 1978). Previous microdialysis studies show 
altered levels of lactate and pyruvate in the painful trapezius muscle compared to healthy 
controls, indicating that they may also participate in chronic orofacial muscle pain (Gerdle 
et al., 2010; Ghafouri et al., 2010; Rosendal et al., 2004a). One suggestion for the altered 
levels are, decreased oxygenation locally in the muscle leading to either increased 
production or reduced degradation of the metabolites (Rosendal et al., 2004a). 
 
Serotonin 
 
5-HT is a monoamine neurotransmitter, important in pain mediation both peripherally and 
centrally (Zeitz et al., 2002). 5-HT derives from tryptophan (Giordano and Schultea, 2004) 
and is mainly found in the gastrointestinal tract where 90 % is located, but also in blood 
platelets and in the CNS. In the CNS it has various functions including regulation of mood, 
appetite, sleep and cognitive functions such as; memory and learning, but is also involved 
in pain inhibition (Lesurtel et al., 2008). 5-HT can stimulate the pain descending inhibition 
system by activating inhibitory interneurons that release endogenous opioids and gamma-
aminobutyric acid (Giordano and Schultea, 2004; Sommer, 2006). In the PNS however, 5-
HT acts as a pain inducer by activating some of its receptors or by promoting the release of 
SP and glutamate which activate and sensitize nociceptors leading to a sensation of pain 
(Mense, 1993, 2003). 
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There are seven 5-HT receptor classes (5-HT1- 5-HT7) with a number of receptors in each 
class, with a total of at least fifteen different receptors (Ernberg, 2009; Glennon and Dukat, 
1991). 5-HT3 is thought to be the most important receptor for pain modulation and with a 
therapeutic potential (Mackie et al., 2000; Ruano et al., 2007). It is the only ligand gated ion 
channel among the 5-HT receptors. The activation of the receptor facilitates the influx of 
sodium, potassium and calcium and is mapped to chromosome 11. 5-HT3 have five 
subunits 5-HT3A-3E each coded by their own gene (HTR3A-E). 
 
Studies have shown that patients with myalgia in the masseter and trapezius muscles have 
higher levels of 5-HT than healthy controls (Dawson et al., 2015; Ernberg et al., 1999; 
Ghafouri et al., 2010) and that 5-HT correlated to pain (Ernberg et al., 1999; Gerdle et al., 
2008b; Rosendal et al., 2004b). Also, intramuscular injections of 5-HT induced pain and 
hyperalgesia (Babenko et al., 1999; Ernberg et al., 2000b). Only two studies have 
investigated the interstitial release of 5-HT in experimental masseter myalgia, were 
repeated acidic saline injections and static tooth-clenching were used as experimental pain 
models. In both studies, no increased levels of 5-HT was reported (Dawson et al., 2015; 
Ernberg et al., 2013). However, TMD myalgia patients had constantly higher levels of 5-HT 
than healthy controls (Dawson et al., 2015). 
 
To our knowledge, no previous study have investigate if jaw muscle pain induced by HS 
leads to a release of muscle biomarkers such as 5-HT, glutamate and other metabolic 
mediators. Since HS is a valid and commonly used experimental pain model, the same 
biomarkers, as in clinical pain, should elevate tentatively after a HS injection.  
 
Granisetron is a 5-HT3 antagonist and is a frequently used drug in radiotherapy- and 
chemotherapy-induced nausea and vomiting in patients with cancer, but also in IBS (Ahn 
and Ehrenpreis, 2002; Vrabel, 2007). There are several 5-HT3 antagonist such as; 
ondasetron, dolasetron and tropisetron which all seem to have an equal effect and few side- 
effects. Granisetron however, has a higher affinity to the 5-HT3-receptor and does not rely 
on the enzyme cytochrome P450 2D6 (CYP2D6) in the metabolism. Previous studies have 
shown that these 5-HT3 antagonists have an effect on localized muscle pain in the lower 
back, neck and face (Christidis et al., 2008; Christidis et al., 2015b; Ettlin, 2004; Stratz and 
Muller, 2004). Thus, granisetron may be a useful therapeutic treatments for chronic 
myalgia.  
 
5-HT3 polymorphisms 
 
In recent years, genetic factors underlying various diseases have received considerable 
attention. There are at least 358 genes thought to be relevant in pain and hyperalgesia 
(Smith et al., 2011). Although no single gene has been shown to cause chronic pain 
conditions, multiple genetic changes (polymorphisms) are thought to be involved. These 
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multiple genetic changes may occur when the genome is copied due to variations in a single 
nucleotide. A single base pair may get left out, added or substituted. These single base pairs 
substitutions create single nucleotide polymorphisms (SNPs). The variations in the DNA 
sequence can affect how we develop diseases, respond to drugs, vaccines and other agents 
(Alwi, 2005).  
 
Several studies have related polymorphisms in the HTR3A/B genes to psychiatric disorders 
(Niesler et al., 2008), only a few studies have shown an association to chronic pain. For 
example, the HTR3A polymorphism was associated with an antidepressant response in 
paroxetine-treated patients (Kato et al., 2006) and showed an involvement in the etiology of 
eating disorders (Hammer et al., 2009). Further, a polymorphism in the HTR3B gene 
(rs1176744) was correlated to major depression in Japanese women (Yamada et al., 2006) 
and bipolar disorder (Hammer et al., 2012). The same SNP showed greater symptoms and 
anxiety in patients carrying the C/C genotype compared to patients with the T-allele 
(Kilpatrick et al., 2011). Also, in the HTR3B gene (rs1176744), subjects carrying the C 
allele showed an association to higher scores on the Pain Catastrophizing Scale, suggesting 
a role of 5-HT pathways in pain catastrophizing (Horjales-Araujo et al., 2013). In addition, 
it has been shown that polymorphisms of HTR3A/B serve as predictors for the 
effectiveness of 5-HT3 antagonists (Niesler et al., 2008) and to the antidepressant response 
of the serotonin selective reuptake inhibitor (SSRI) paroxetine (Kato et al., 2006). 
Furthermore, subjects with a SNP (rs1176744) in the HTR3B gene, showed an increase 
response to 5-HT (Krzywkowski et al., 2008) indicating that subjects carrying this SNP 
could be more sensitive to pain. 
 
Taken together, these findings indicate that polymorphisms in the HTR3A/B genes may be 
involved in the pathogenesis of depressive disorders and the effect of 5-HT3 antagonists. 
Since pain and depression share the same pathways (Delgado, 2004), there are reasons to 
believe that the 5-HT polymorphisms also may be involved in the pathophysiology of 
chronic myalgia.  
 
Experimental pain models 
 
Experimental pain models are developed to mimic the clinical setting, in order to improve 
the knowledge of the pathophysiology underlying chronic pain conditions (Arendt-Nielsen 
et al., 2007). Human experimental pain models are the link between basic science and 
clinical research (Reddy et al., 2012). There are a number of different experimental pain 
models that can be divided into endogenous and exogenous methods. Endogenous methods 
means pain induced by natural, endogenous stimuli, and exogenous methods involve 
experimental pain induced by externally applied stimuli (Graven-Nielsen, 2006; Graven-
Nielsen et al., 2003; Staahl and Drewes, 2004). The experimental pain models can be used 
in patients with pain conditions but also in healthy controls. An experimental pain model is 
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thought to trigger the nociceptive system by activating the peripheral nerve cells (Reddy et 
al., 2012). The pain evoked is then assessed and evaluated with different tools such as; the 
visual analogue scale (VAS), the numeric rating scale (NRS), pain drawings and pressure 
pain thresholds (PPT). 
 
In this project we have used both endogenous and exogenous methods to study muscle pain, 
namely; acidic saline injections, HS injections (exogenous methods) and static tooth-
clenching (endogenous method). 
 
Acidic saline injections 
 
Acidic saline is a solution with a lowered pH (pH 3.3- pH 5.2) by the supply of protons 
(H+). H+ play a key role in the upcoming experimental muscle pain by lowering the pH of 
the tissue, triggering the chemo sensitive nociceptors such as acid-sensing ion channels 
(ASIC1 and/or ASIC3) and/or the transient receptor potential vanilloid 1 on primary 
afferent neurons (Frey Law et al., 2008). 
 
In animal studies, injections of acidic saline (pH 4) intramuscularly have been shown to be 
a successful experimental pain model causing a long-lasting hyperalgesia, mimicking 
chronic myalgia. In one study, repeated intramuscular injections of acidic saline into the 
gastrocnemius muscle of rats evoked a long lasting mechanical hyperalgesia with a duration 
up to 30 days (Sluka et al., 2001). In another study repeated injections of acidic saline (pH 
4, 20 μL) with 2 days apart, into the rat masseter muscle caused long-lasting mechanical 
allodynia for up to 38 days (Lund et al., 2010). However, in contrast, another study did not 
show any long-lasting allodynia in the rat masseter muscle after two repeated injections of 
acidic saline (pH 4, 150 µL) 2–5 days apart (Ambalavanar et al., 2007). In a human study, 
mild to moderate muscle pain with pain referral and mechanical allodynia was induced by a 
single injection of a buffered acidic saline infusion (pH 5.2) into the tibialis muscle, that 
lasted for 20 min (Frey Law et al., 2008). Furthermore, at the same time our research group 
performed two experimental studies with acidic saline injections. In one of them, repeated 
injections in the masseter muscle failed to cause a long-lasting hyperalgesia in humans 
(Castrillon et al., 2013). In the other, which was a microdialysis study, injections of acidic 
saline in the masseter muscle did not cause the release of algesic substances such as 5-HT, 
glutamate, pyruvate, lactate and glucose (Ernberg et al., 2013).  
 
Hypertonic saline injections 
 
An often used experimental pain model is HS injections. It is a solution that contains 1 to 
23.4 % NaCl compared to normal (isotonic) saline solution containing 0.9 % NaCl (in the 
human body). It is considered to be a valid model of TMD myalgia (Svensson et al., 
2001b). It has an acute character and causes a pronounced sensation of deep, diffuse pain, 
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and pain referral (Graven-Nielsen et al., 2001; Jensen and Norup, 1992; Stohler and Lund, 
1994; Vecchiet et al., 1993). The pain intensity and character depends on factors or 
variables such as the volume of HS solution, concentration and infusion rate (Graven-
Nielsen, 2006; Graven-Nielsen et al., 1996). However, the painful sensation also depends 
on the individual differences for pain perception in the test group. The pain inducing effect 
of HS injections has been suggested to occur direct or indirect, by activation of sodium 
channels (Cairns et al., 2003), but also by the release of inflammatory substances such as; 
glutamate and SP (Garland et al., 1995; Tegeder et al., 2002).  
 
Several previous studies have showed that biomarkers such as; 5-HT, glutamate and other 
metabolites (lactate and pyruvate), are higher in patients with chronic muscle pain 
conditions in the masseter and trapezius muscles compared to healthy controls (Castrillon et 
al., 2010; Ernberg et al., 1999; Gerdle et al., 2010; Ghafouri et al., 2010; Rosendal et al., 
2004b; Tegeder et al., 2002; van Hall et al., 2002). However, in order to increase the 
validity of the experimental pain model, the same biomarkers released in clinical pain 
should also be increased after a HS injection.  
 
Experimental tooth-clenching 
 
Previous studies have suggested that self- reported tooth-clenching is a risk factor in 
developing TMD myalgia (Huang et al., 2002; Velly et al., 2003) by causing a disturbed 
blood flow due to overloaded muscles, leading to ischemia and the release of inflammatory 
biomarkers which activate peripheral afferents (Barr and Barbe, 2002; Monteiro and Kopp, 
1989; Stauber, 2004). It is also suggested that repetitive muscle work may maintain chronic 
muscle pain due to temporal summation (Bennett, 2012). Previous studies have shown that 
excessive chewing evoked muscle pain and fatigue, suggesting that TMD pain is more alike 
an exercise-induced muscle pain (Koutris et al., 2009; Staahl and Drewes, 2004).  
 
In another study, a 20-minute repetitive tooth-clenching task with 50 % of the maximum 
voluntary clenching force (MVCF), caused increased pain in TMD myalgia patients 
compared to healthy controls. Also, TMD myalgia patients had higher levels of 5-HT 
compared to healthy controls during the entire microdialysis, but it did not increase due to 
tooth-clenching, suggesting that other biomarkers may trigger the nociceptors and cause pain 
(Dawson et al., 2015).  
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AIMS 
 
The general aim of this thesis was to increase our knowledge of the peripheral pain 
mechanisms and pathophysiology underlying TMD myalgia.  
 
 
Specific aims 
 
 To evaluate the effect of the 5-HT3-antagonist granisetron on experimentally 
induced muscle pain. 
 
 To investigate if 5-HT3 polymorphisms contribute to pain perception and the 
efficacy of the 5-HT3 antagonist granisetron on experimentally induced muscle 
pain. 
 
 To investigate the role of muscle biomarkers (5-HT, glutamate, lactate, pyruvate, 
glucose and glycerol) and pro- and anti-inflammatory cytokines (IL-1β, IL-2, IL-
4, IL-5, IL-6, IL-7 IL-8, IL-10, IL-12, IL-13, TNF, IFN- γ and GM-CSF) in the 
pathophysiology underlying TMD myalgia in a human experimental and a clinical 
study.  
 
 
 
  
13 
 
HYPOTHESES 
 
The following hypotheses were tested: 
 
Study I 
 Muscle pain induced by two repeated acidic saline injections into the masseter muscle 
of healthy volunteers can be blocked by the 5-HT3 antagonist granisetron. 
 The pain-reducing effect by granisetron is better in men than in women. 
 
Study II 
 Polymorphisms in the serotonergic system are of importance for pain transmission 
and for the efficacy of the 5-HT3 antagonist granisetron on experimentally induced 
muscle pain. 
 There are sex differences due to specific HTR3A/B genotypes in pain response after 
experimentally evoked muscle pain and the analgesic effect of granisetron. 
 
Study III 
 Muscle pain induced by HS in the masseter muscle causes a significant release of 5-
HT, glutamate, lactate, pyruvate, glucose and glycerol. 
 The release of muscle biomarkers are higher in women than in men.  
 
Study IV 
 The levels of pro- and anti-inflammatory cytokines are significantly higher in patients 
with TMD myalgia both at rest and after a repetitive tooth-clenching task. 
 The release of cytokines are correlated with pain intensity and fatigue.  
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MATERIALS AND METHODS 
 
The methods and selection of participants were approved by the Regional Ethical review 
board in Stockholm, Sweden (Study I: 2008/362-31; Study II: 2011/1955-31/2; Study III: 
2008/362-31; Study IV: 2009/2047-32;), the Medical Products Agency in Uppsala, Sweden 
(Study I: 2008-000746-32; Study II: 2011-006206-27, Dnr 151:2011/96710), the Swedish 
Data Inspection Board in Stockholm, Sweden (Study II: Dnr 54-2013) and the Local 
Radiology Committee (Study III: Dnr 11/08) at Karolinska University Hospital in 
Huddinge, Sweden. 
 
All studies were conducted at the Department of Dental Medicine at the Karolinska 
Institutet, Huddinge, Sweden and followed the guidelines of the Declaration of Helsinki as 
well as the Good Clinical Practice guidelines. All participants were over 18 years of age 
and were recruited among staff, colleagues and students at the Department, but also by 
advertisements. All participants received written and verbal information of the study before 
participating and gave their written consent.  
 
Healthy participants 
 
A number of 134 healthy participants, 77 women and 57 men, participated in the studies (I-
VI) (Table 1). The participants were age- and sex-matched.  
 
Inclusion criteria were: age over 18 years and a good general health.  
 
Exclusion criteria for all studies were: no current or history of pain from the orofacial 
region. In addition the exclusion criteria for study I were: a) migraine and/or tension-type 
headache; b) use of any kind of medication except for contraceptives 24 hours preceding 
the study day; c) smoking; d) pregnancy or lactation; and e) a history of allergic reactions to 
granisetron. For studies II-IV the exclusion criteria were: diagnosed systemic muscular or 
joint diseases such as: a) fibromyalgia; b) rheumatoid arthritis; c) whiplash-associated 
disorder; d) neuropathic pain or neurological disorders; e) pregnancy or lactation; f) high 
blood pressure and g) use of antidepressants or analgesics during the last three days. 
 
Patients  
 
Twenty female patients with TMD myalgia participated in Study IV (Table 1). The patients 
were referred to the Section of Orofacial Pain and Jaw Function at the Department of 
Dental Medicine, Karolinska Institutet, Huddinge, Sweden.  
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The inclusion criteria were; age over 18 years and a diagnosis of TMD myalgia according 
to the DC/TMD (Schiffman et al., 2014). 
 
The exclusion criteria were: systemic muscular or joint diseases, such as a) fibromyalgia; b) 
rheumatoid arthritis; c) whiplash-associated disorder; d) neuropathic pain or neurological 
disorders; e) pain of dental origin; and f) use of analgesics of non-steroidal anti-
inflammatory drugs during 48 hours before microdialysis.  
 
Table 1. The number of healthy participants and their age (years). Values are expressed as 
number of participants and as mean (± SD) for age. 
 
 
Methods 
Assessment of pain 
Visual analogue scale and Numeric rating scale 
 
In the studies I and II, a 0-100-mm VAS scale was used to assess the pain intensity after 
experimentally induced muscle pain in the masseter muscles, and in studies III and IV a 0-
10 NRS scale was used. The scales were marked with the end-points “no pain” and “the 
worst pain ever experienced”. 
Study I II III IV 
Healthy participants 
    
All 28 60 26 20 
Men 14 30 13 0 
Women 14 30 13 20 
Age     
All 25.8 ±2.4 26.2 ± 3.9 25.7 ± 4.3 29 ± 11 
Men 27.8 ± 6.2 27.1 ± 4.4 25.7 ± 4.3 0 ± 0 
Women 23.1 ± 1.8 25.6 ± 3.6 26.1 ± 4.4 29 ± 11 
     
Patients  
(TMD myalgia) 
    
All - - - 20 
Men - - - 0 
Women - - - 20 
Age     
All - - - 31.2 ± 9.8 
Men - - - 0 ± 0 
Women - - - 31.2 ± 9.8 
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Pain drawings 
 
Pain drawings were used to assess the pain area and or pain referral in studies I-III. 
Participants were instructed to mark their pain distribution on face charts with the lateral 
side of the head. For the analysis, the face charts were placed over a transparency with 1.5-
1.5 mm squares and the full squares were counted. Squares partly inside the border i.e. two 
half squares or three 1/3 squares were added up to full squares, in line with previous study 
(Christidis et al., 2008). The area were expressed in arbitrary units (au). 
 
Pressure pain threshold 
 
PPT was assessed in all studies (I-IV) with an electronic pressure algometer (Somedic Sales 
AB, Höör, Sweden). The algometer was calibrated at study start and the zero level was 
balanced before each measurement. The tip of the algometer was 1 cm2 and covered with a 
1 mm thick rubber pad. A standardized pressure of 50 kPa/s was used. The tip was placed 
on the most prominent part of the masseter muscle and the participants were instructed to 
press a signal button as soon as the pressure turned into pain. The procedure was first tested 
on the right thumb on the dorsal side. The PPT was recorded bilaterally over the masseter 
muscles as well as over a reference point, which was the tip of the right index finger. The 
reference point was used in order to register if any possible systemic effects occurred by the 
treatments in studies I and II. 
 
DNA analysis 
 
In study II, a 4 ml blood sample was taken from a peripheral vein using a Vacutainer tube 
containing ethylenediaminetetraacetic acid solution. The blood sample was immediately 
stored at -80°C until analysis. If a blood sample was not able to be collected, a saliva 
sample was instead collected, using the OG-500 kits (DNA Genotek Inc, Ontario, Canada). 
The saliva samples were stored in room temperature according to the manufacturer’s 
instructions. Prior to the analysis, DNA was extracted from blood or saliva using standard 
methods at the Department of Molecular Medicine and Surgery (MMK), Karolinska 
University Hospital Solna, Stockholm, Sweden. The HTR3A/B SNPs (rs1062613 and 
rs1176744) were genotyped with the Applied Biosystems Quantstudio 7 Flex Real-Time 
PCR System from Thermo Fischer Scientific, Carlsbad, CA by using allele specific 
Taqman minor groove binder probes labeled with fluorescent dyes Fluorescein and VIC, 
according to the manufacturer´s protocol. Polymerase chain reaction (PCR) is a technique 
used to amplify a single copy or a few copies of a segment of DNA, creating thousands to 
millions of copies of a particular DNA sequence (Holland et al., 1991). This was done 
according to previous studies (Johansson et al., 2012; Nikamo et al., 2014; Nikamo et al., 
2015). 
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Questionnaires 
 
Questionnaires of psychological nature were assessed in studies III and IV in order to 
measure the level of anxiety and stress in adults. The questionnaires used were; the State-
Trait Anxiety Inventory (STAI) and the Perceived stress scale-14 (PSS-14).  
 
State-trait anxiety inventory  
 
The Swedish version of the State-trait anxiety inventory (STAI) was used to assess trait-
anxiety. The STAI questionnaire contains two scales with twenty questions to determine the 
anxiety level. The first scale measures anxiety of an event, and the second scale measures 
anxiety as a personal characteristic. The scores range from 20 to 80 where higher scores 
indicate higher levels of anxiety. Scores ≤ 30 indicate no or low signs of anxiety, but scores 
> 30 show high signs of anxiety. In both studies (III, IV) the focus was on a general and 
long-standing quality of trait anxiety since it is very common in patients with chronic pain 
(Spielberger, 1975). The Swedish version of the STAI was used (Forsberg and Bjorvell, 
1993). 
 
Perceived stress scale-14 
 
The PSS-14 questionnaire comprises 14 stress- related questions of a general nature. It 
contains questions about feelings and thoughts during the last month, situations in life 
perceived as stressful and the current levels of stress. The maximum scoring is 56 were 
scores of 24 or below are considered as normal in healthy participants (Cohen et al., 1983). 
The Swedish version of the PSS-14 was used (Nordin and Nordin, 2013). 
 
Microdialysis 
 
Microdialysis is a minimally invasive technique used to study the release of biomarkers in 
different tissues in the body (Ungerstedt, 1991). The technique is similar to a capillary 
blood vessel where the molecules diffuse through endothelial cells to blood cells. The 
technique contains a microdialysis catheter connected to a micro infusion pump to perfusate 
the tissue with perfusion medium. On the tip of the catheter, a semipermeable membrane is 
glued, allowing molecules in the extracellular fluid to diffuse across the membrane and be 
collected by the catheter (Figure 2) (Lindefors et al., 1987). The cut off value of the probe, 
determines which molecules will pass through the membrane. The fluid (dialysate) 
collected by the catheter in microvials, is analyzed. This technique was used in studies III 
and IV to sample several biomarkers from the masseter muscle. 
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Figure 2. Illustration of the microdialysis technique containing a catheter with a 
semipermeable membrane at the tip, a micro infusion pump and microvials collecting the 
buffered ringer-acetate solution. In study III, the needle was inserted through a plastic 
guiding tool with pre-made holes (45° and 90° angles), confirming that the HS injection 
targeted the same location in the masseter muscle. In study IV, a split able introducer was 
used to insert the catheter intramuscularly. 
 
Study III 
 
Intramuscular microdialysis in the masseter muscle was done to sample 5-HT, glutamate, 
lactate, pyruvate, glucose and glycerol, and to estimate nutritive muscle blood flow. The 
most prominent point of the masseter muscle was palpated and chosen and a local 
anesthetic patch (EMLA® patch, lidocaine/prilocaine 25 mg/25mg, AstraZeneca AB, 
Södertälje, Sweden) was applied for 30 minutes. After removing the patch from the muscle 
and cleaning it with injection swabs (70 % isopropyl alcohol), a sterile flexible 
microdialysis catheter (Ø 0.5 mm; membrane length 10 mm, total length 30 mm; molecular 
cut off: 6 kDa MAB 11, Microbiotech AB, Stockholm, Sweden) was inserted in the muscle 
via a 6-mm thick sterile plastic plate (10 × 40 mm) with pre-made holes, one at 90° angle to 
the surface, and the other at 45° angle. The plastic plate was used so that the catheter was 
placed in close proximity to the needle in the muscle, in order to reassure that the HS 
injection targeted the same area in the masseter muscle (Figure 2). The catheter was 
inserted through the 45° angle canal and connected to a micro infusion pump (MAB 140, 
Microbiotech AB, Stockholm, Sweden) and perfusated with a buffered ringer-acetate 
solution containing 0.5 mM ringer-lactate. The perfusion rate was 5 µl/min. Dialysates of 
120 µL were collected every 20 minutes in microvials. Samples were immediately frozen at 
-70°C. Relative recovery of the dialysates was determined by adding 3.0 µL [14C]-lactate 
(specific activity: 7.4 MBq/mL; PerkinElmer Life Sciences, Boston, MA, USA) (Scheller 
and Kolb, 1991), and the blood flow was estimated by adding 3.0 µL 3H2O (Gerdle et al., 
2008b; Rosendal et al., 2004b). 
 
19 
 
Study IV 
 
Intramuscular microdialysis was performed in the masseter muscle to sample the pro- and 
anti-inflammatory cytokines; IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7 IL-8, IL-10, IL-12, IL-13, 
TNF, IFN- γ and GM-CSF. The most prominent point of the masseter muscle was chosen 
and anaesthetized superficially with a local injection (0.5 ml) of Xylocaine (20 mg/ml) 
making sure not to anaesthetize the underlying muscle. A sterile split able introducer was 
inserted at a 45° angle in the masseter muscle at a depth of approximately 40 mm from the 
skin surface. A sterile microdialysis catheter (High cut off Brain Microdialysis Catheter; 
membrane length 20 mm, total length 60 mm; molecular cut off: 100 000 Dalton, CMA 71 
Microdialysis AB, Solna Sweden) was then inserted in the muscle, and the introducer was 
removed by splitting the plastic tube (Figure 2). A micro infusion pump (CMA 107, 
Microdialysis AB, Solna Sweden) was connected to the probe. The perfusion rate was 5 
µl/min with a ringer-acetate solution containing 0.5 mM ringer-lactate. Micro dialysates 
were sampled every 20 minutes in microvials. Samples were stored at -80°C. 
 
Relative recovery 
 
The dialysate samples do not reflect the true values of the extracellular concentration due to 
several factors; the flow rate, the diffusion rate through the tissue, the area and weight cut 
off of the dialysis membrane and the composition of the perfusate (Gerdle et al., 2014). 
Relative recovery (RR) describes the concentration of the dialysate in relation to the 
extracellular fluid. Factors that affects the RR are; a) the osmotic pressure b) the 
temperature and c) the concentration gradient (Dahlin et al., 2010). When small molecules 
such as 5-HT and glutamate are sampled, a cut off of 20 kilo Dalton (kDa) or less can be 
used, whereas for larger molecules such as cytokines, a higher cut off is required, usually 
100 kDa. The interstitial concentration can be calculated by using the mathematic formula: 
Ci = [Cd - Cp]/ RR + Cp where Cd was the dialysate concentration and Cp, the perfusate 
concentration (Scheller and Kolb, 1991).  
 
To determine the RR of each substance, 5 µL of each dialysate or perfusate was pipetted 
into a counting vial with 3 µL of scintillation fluid (High-flash Point, Universal LSC-
Cocktail, ULTIMA GOLD™, PerkinElmer, Inc.) and vortexed. A formula was used to 
calculate the RR i.e. (cpmp-cpmd)/cpmp, where cpmp was counts per min of the perfusate, 
and cpmd was counts per min of the dialysate. To calculate counts per minutes (cpm) a 
liquid scintillation beta counter (Beckman LS 6000TA; Beckman Instruments, Inc., 
Fullerton, CA, USA) was used for [14C]-lactate and 3H20. Nutritive blood flow was 
estimated using 3H2O with the formula: 1/ (cpmd/cpmp), where cpmd was 
3H2O counts per 
min in the dialysate and cpmp, in the perfusate (Gerdle et al., 2008b; Rosendal et al., 
2004b). In study III, the RR and blood flow were analyzed for the whole microdialysis, for 
all time-points. 
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Analyzes of biomarkers 
 
In study III, the concentrations of 5-HT were analyzed with high-pressure liquid 
chromatography, with electrochemical detection according to a previous study (Ghafouri et 
al., 2010). The limit of detection (LOD) for the 5-HT was 20 fmol/10 µL. Other biomarkers 
(glutamate, glucose, lactate, pyruvate and glycerol) were analyzed with the ISCUS® 
analyzer (ISCUS, Dipylon Medical AB, Solna, Sweden). The limit of detection (LOD) of 
glutamate was 1.0 µmol/L, for glucose and lactate 0.1 mmol/L, for pyruvate 10 µmol/L and 
for glycerol 0.22 mg/mL. Concentrations that were 50 % below LOD were reported as 
having the same concentration as the LOD. Concentrations that were 50 % above LOD 
were reported as obtained. These analyzes were done at the Painomics Laboratory, 
Rehabilitation Medicine, Department of Medical and Health Sciences, Linköping 
University, Sweden. 
 
In study IV, the concentrations of the cytokines were analyzed with Luminex technology 
and Bioplex® (Multiplex System, Bio- Rad) and multiplex immunoassay panels 
(Milliplex® map kit, Human High sensitivity, T cell magnetic bead panel, 96-well plate 
assay, Merck Millipore Darmstadt, Germany) according to the manufacturer's manual. The 
analysis were done at the research lab at the Department of Dental Medicine, Huddinge, 
Sweden. The LOD for each cytokine was; TNF, 0.43 pg/mL; IL-1β, IL-2, IL-5 and IL-12, 
0.49 pg/mL; IL-4, 1.83 pg/mL; IL-6, 0.18 pg/mL; IL-7, 0.37 pg/mL; IL-8, 0.31 pg/mL; IL-
10, 1.46 pg/mL; IL-13, 0.24 pg/mL; IFN-γ, 0.61 pg/mL and GM-CSF, 1.22 pg/mL.  
 
Experimental protocol 
 
A randomized, placebo-controlled and double-blinded design was used for studies I-III, and 
a case control design for study IV. A randomization list performed by a computer was used 
to balance the injections and administration of granisetron or placebo in studies I and II, 
and the injections with HS or placebo in study III. The participants were seated in a relaxed 
position in a conventional dental chair during all experiments.  
 
Study I 
 
First, participants were screened with a clinical examination according to the Research 
Diagnostic Criteria for TMD (RDC/TMD) Axis I (Dworkin and LeResche, 1992) in order 
to establish that the inclusion criteria were fulfilled. Baseline recordings of PPT were 
assessed, and thereafter participants received a bilateral injection of acidic saline (9 mg/mL, 
pH 3.3) into the masseter muscles (day 1). An infusion pump (infusion rate 1200 μL/min; 
Harvard Infusion Pump 22, Harvard Apparatus, Great Britain) was used in order to induce 
simultaneous bilateral pain. Two days later (day 3), pain intensity (VAS) and PPT were 
assessed in the masseter muscles. The masseter muscle on one side was then pre-treated 
with granisetron (Kytril®, 1 mg/mL, Roche, Stockholm, Sweden) and the contra-lateral 
side with placebo (isotonic saline, pH 6). Two minutes later, a bilateral simultaneous 
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injection of acidic saline followed. The needles were kept in the masseter muscles between 
injections to reassure that the treatment injections targeted the same site as the acidic saline 
injections. The pain evoked was assessed on a visual analogue scale (VAS) immediately 
after the injections and then every 15th second until pain had subsided to a maximum extent 
of 300 sec. Pain duration (sec) and pain area (au) were also assessed. The PPT recordings 
were made at baseline and 5, 15, 30, 45 and 60 minutes after the second injection of acidic 
saline. After 7 days (day 10), the pain distribution (au) and PPT were re-assessed.  
 
Study II 
 
Participants were first screened with a clinical examination according to the Research 
Diagnostic Criteria for TMD (RDC/TMD) (Dworkin and LeResche, 1992). Blood or saliva 
were sampled for genetic analyzes of the HTR3A/B polymorphisms (rs1062613, 
rs1176744). A bilateral injection of hypertonic saline (HS, 5.5 %, 0.2mL) was injected into 
the masseter muscles (injection 1) to evoke pain, using an infusion pump (infusion rate 
1200 μL/min; Harvard Infusion Pump 22, Harvard Apparatus, Great Britain). Thirty 
minutes later, the masseter muscle on one side was pre-treated with 0.5 mL of granisetron 
(Kytril®, 1 mg/mL, Roche, Stockholm, Sweden), and on the contralateral side with 0.5 mL 
of isotonic saline (9 mg/mL). Two minutes later, another bilateral HS injection (injection 2) 
was injected. Pain intensity (VAS) was assessed immediately after the injections and then 
every 15th second until pain had subsided to a maximum extent of 300 sec. After each HS 
injection, pain intensity, pain duration, pain area and PPT were assessed.  
 
Study III 
 
Participants were examined with a clinical examination according to the Research 
Diagnostic Criteria for TMD (RDC/TMD) Axis I (Dworkin and LeResche, 1992). After 
inclusion, questionnaires of psychological nature (STAI and PSS-14) were used to measure 
the level of anxiety and stress. Thereafter, bilateral intramuscular microdialysis in the 
masseter muscles was performed to sample 5-HT, glutamate, lactate, pyruvate, glucose and 
glycerol. Microdialysis was performed during 3 hours. After 2 hours of stabilization 
(trauma phase), HS (5.5 %, 0.2 mL) was injected into the masseter muscle on one side, and 
isotonic saline (placebo: 0.9 %, 0.2 mL) into the contra-lateral side, in close vicinity to the 
microdialysis catheter in a randomized order. Pain intensity (VAS), pain duration (sec) and 
pain area (au) were assessed. Furthermore, PPT was assessed, before and after 
microdialysis. 
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Study IV 
 
First, a clinical examination according to the Diagnostic Criteria for TMD (DC/TMD) 
(Schiffman et al., 2014) was performed, then the maximal voluntary clenching force 
(MVCF) and PPT were assessed. After baseline registrations and local anesthesia, the 
microdialysis started. After 120 minutes of rest (trauma phase), baseline assessments of 
pain intensity and fatigue were made (120-140 min) followed by a 20-minute repetitive 
tooth-clenching task (140-160 min) at 50 % of MVCF (kg). A bite-force transducer 
(Aalborg University, Denmark) was used to assess the MVCF, and placed between the 
molars on the most suitable side, from a dental point of view (Figure 3). The participants 
were instructed to bite repeatedly every 30-seconds, followed by 30-seconds of rest during 
20 minutes. Pain intensity (NRS 0-10) and fatigue (Borg scale 6-20) were assessed. The 
microdialysis continued one hour after the tooth-clenching task. PPT was assessed before 
and after microdialysis. The STAI and PSS-14 questionnaires were assessed to measure the 
levels of anxiety and stress. 
 
Figure 3. Illustration of the experimental 
tooth-clenching task that was performed in 
study IV during microdialysis (140-160 min). 
Visual feed-back was displayed on the bite-
force transducer so that the participants 
could maintain a steady bite-force (50 % of 
their mean MVCF). 
 
 
Statistics 
 
Data was analyzed with SigmaPlot for Windows, version 11 (Systat Software Inc., 
Chicago, IL, USA in studies I-IV), SPSS software version 15.0 (SPSS Inc. Chicago, IL, 
USA in study III) and STATISTICA, StatSoft Dell Software version 12.0 (Round Rock, 
Texas USA in study IV). To test if the data was normally distributed, the Shapiro-Wilk’s 
test was used (studies I- IV). In studies II-IV the data was not normally distributed and 
therefore non-parametric statistical analyzes were used. For the descriptive statistics the 
mean and standard deviation were used in study I, and median and IQR were used in studies 
II-IV. A power calculation was done in each study to include a sufficient number of 
participants in order to detect a statistically significant difference. For all studies a 
significance level of 5 % was set. 
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Changes in pain variables  
 
In study I, parametric statistics were used and two-way mixed model ANOVA was used to 
analyze pain intensity after each injection and to compare differences between sides after 
pre-treatment with granisetron or placebo. Time was set as the repeated factor, and pain 
intensity (VAS) as the dependent factor. The Holm Sidak test was used for multiple 
comparisons and served as a post-hoc test.  
 
In study II, the Wilcoxon test was used to analyze differences in pain variables after 
injections. ANOVA on ranks (Kruskall-Wallis test) or Mann-Whitney U-test was used to 
test the effect of the different SNPs on pain intensity, pain duration, pain area and PPT after 
HS injection and pre-treatment with granisetron. 
 
In study III, The Mann-Whitney U-test was used to analyze differences in pain intensity 
between the HS and control side at the different time-points but also if there were any 
differences in the maximum pain intensity between sides. Spearman’s correlation test, 
adjusted for multiple testing with Bonferroni correction, was used for analyzes of 
significant correlations between pain and the release of biomarkers. 
 
In study IV, the Wilcoxon test was used to compare the time points 140 minutes (BL) and 
160-220 minutes within each group. The Mann-Whitney U-test was used to analyze 
differences in the mean values (20-220 min) between groups, but also if there were any 
differences between groups at the time points 160 minutes (after tooth-clenching). In 
addition, the Mann-Whitney U-test was used to compare cytokine levels, pain intensity and 
fatigue (due to tooth-clenching) within and between groups. The Spearman’s correlation 
test with Bonferroni correction for multiple testing, was used to analyze correlations 
between pain intensity, level of fatigue and cytokine levels. 
 
In the thesis, ANOVA on ranks (Kruskall-Wallis test) was performed to investigate the 
differences in pain intensity, pain duration and pain area between the different experimental 
pain models. The Mann-Whitney U-test was used to analyze differences in pain intensity, 
pain duration and pain area after pre-treatment with granisetron or placebo. 
 
Changes in pressure pain thresholds 
 
In study I, one-way repeated measures ANOVA was used to test the significance of the 
changes in PPT. The PPT values after the injections were normalized to baseline, i.e. the 
relative changes (%) were used in the statistical analyzes. 
 
In study II, the Wilcoxon test was used to analyze differences in PPT after injections. The 
values were normalized to the baseline value i.e. expressed in percent change. The mean 
values of the PPT (PPTmean) at the different time points (5, 10, 15, 20, 25 and 30 min) were 
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calculated in order to compare the effect of different SNPs on changes of PPT. The PPTmean 
value was normalized to the baseline value. 
 
In study III and IV, the differences in PPT between sides before and after microdialysis was 
analyzed with unpaired t-test. 
 
In the thesis, the t-test was used to analyze the relative changes (%) in PPT after pre-
treatment with granisetron or placebo.  
 
Changes in levels of biomarkers 
 
In study III, the Friedman-test was used to analyze changes in biomarkers (5-HT, 
glutamate, lactate, pyruvate, glucose and glycerol) and pain levels over time on each side 
during microdialysis. A post-hoc test with Bonferroni correction was used when a 
significant difference was indicated by the Friedman-test. 
 
In study IV, the changes in interstitial levels of cytokines over time was analyzed with 
repeated measures analysis of variance (RM ANOVA). However, since the Sphericity test 
was significant for all cytokines except IL-1β, and attempts to transform data did not 
change this, non-parametric statistics were used. The Mann-Whitney U-test was used to 
analyze differences in cytokine levels between groups, by calculating and comparing the 
mean of all 11 dialysate samples (0-220 min). The Friedman-test analyzed changes in the 
levels of cytokines over time. Bonferroni correction was used to adjust for multiple testing. 
 
Sex differences 
 
In study I, unpaired t-test was used to test for significance between sexes in pain intensity, 
pain area and pain duration after acidic saline injections, but also in PPT at baseline (day 1) 
and before injections (day 3). 
 
In study II, the Mann-Whitney U-test was used to analyze sex differences in pain variables, 
efficacy of granisetron and PPT after HS injections. 
 
In study III, the Mann-Whitney U-test was used to test sex differences in pain intensity, 
pain duration, pain area and scoring of questionnaires (STAI and PSS-14). Unpaired t-test 
was used to test differences in PPT between sexes before and after microdialysis.  
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RESULTS AND DISCUSSION 
Changes in pain variables  
 
All experimental pain models respectively induced pain mainly localized to the masseter 
muscle, but the HS injections (studies II and III) caused pain with referral to adjacent regions 
such as the temporalis, teeth and forehead in some participants.  
 
Acidic saline injections (study I) caused a low-moderate pain intensity for approximately 2 
minutes. HS injections (studies II and III) evoked pain of moderate intensity during 
approximately 4-5 minutes. Tooth-clenching (study IV) increased pain and fatigue in TMD 
myalgia patients and increased the level of fatigue in healthy controls. There was a difference 
in pain intensity and fatigue before and after tooth-clenching between patients and controls 
(P’s < 0.001). HS injections caused higher pain intensity than acidic saline injections and 
experimental tooth-clenching, in healthy controls (P < 0.001), but in TMD myalgia patients, 
the pain intensity increased to the same magnitude as HS injection in healthy participants 
(Figure 4). 
 
Figure 4. Graph showing the mean (SD) peak pain intensity (VAS 0-100 mm) in the masseter 
muscles of healthy participants and patients with TMD myalgia, in each experimental pain 
model. I = study I; II = study II; III = study III; IV= study IV. TC = Tooth-clenching. 
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The differences in pain duration and pain area between HS injections and acidic saline 
injections are shown in Figure 5.  
 
Figure 5. Graph showing the mean (SD) pain duration (sec) and painful area (au) in the 
masseter muscle of healthy participants after experimentally induced muscle pain with acidic 
saline and HS injections. The HS injections caused significantly longer pain duration (P < 
0.001) and larger pain area (P < 0.05) compared to acidic saline injections. I = study I; II = 
study II; III = study III. 
* = Significant differences between pain variables (P < 0.05). 
 
The results illustrates that different experimental pain models induce muscle pain of different 
intensity, duration and area. Results from studies II and III show that HS injections caused a 
deep, diffuse pain with pain referral, in line with previous studies with no side effects 
(Graven-Nielsen, 2006). But, since it causes a short-lasting pain of a more acute character, 
another experimental pain model that mimics the clinical situation in a better way would be 
preferable.  
 
In animal studies, repeated intramuscular injections of acidic saline caused a long-lasting 
allodynia with pain referral (Lund et al., 2010; Sluka et al., 2001). On the contrary, in another 
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study, repeated acidic saline injections in rodents did not cause long-lasting allodynia 
(Ambalavanar et al., 2007). In a human experimental study, a single injection of buffered 
acidic saline (pH 5.2) caused a mild to moderate pain with pain referral and mechanical 
allodynia lasting for 20 minutes (Frey Law et al., 2008).  
 
With this in mind, it was relevant to investigate if the similar experimental pain model as 
used in animal studies, with repeated intramuscular acidic saline injections, would generate 
similar results in humans. However, results from study I showed that repeated intramuscular 
injections of acidic saline in the masseter muscle caused a short-lasting, low-moderate pain 
with no pain referral, thus was unsuccessful to better mimic the clinical condition. This is 
supported by a previous study were repeated injections of acidic saline in the masseter muscle 
failed to induced a long-lasting hyperalgesia (Castrillon et al., 2013). However, in contrast to 
the previous human study that used buffered acidic saline (Frey Law et al., 2008), these 
human studies used un-buffered acidic saline which could be one explanation for the 
contradictory results. Nevertheless, even though, an enhancement of the experimental pain 
model has been tested, using a buffered solution, it did not cause a long-lasting hyperalgesia 
in the masseter muscle (unpublished results). Furthermore, in a microdialysis study, acidic 
saline infusions did not increased the interstitial levels of algesic substances in the masseter 
muscle (Ernberg et al., 2013). Thus, repeated intramuscular acidic saline injections does not 
seem to be a valid experiment pain model for chronic muscle pain. 
 
Excessive muscle work is another experimental pain model that has been used in several 
studies to investigate the pathophysiology behind musculoskeletal pain (Armstrong, 1984; 
Gerdle et al., 2008b; Larsson et al., 2008; Mengshoel et al., 1995; Miles and Clarkson, 1994; 
Strom et al., 2009). Since overload due to bruxism is suggested to be a risk factor for TMD, 
there are a number of studies examining different experimental tooth-clenching tasks and the 
effect on pain (Farella et al., 2010; Hedenberg-Magnusson et al., 2006; Torisu et al., 2007). In 
line with a previous study (Dawson et al., 2015), results from study IV show that tooth-
clenching induced higher pain intensity and fatigue in patients with TMD myalgia than in 
healthy controls (P’s < 0.001). In patients, the pain intensity increased after tooth-clenching 
to a similar intensity as HS injections induced in healthy controls. However, only one healthy 
participant reported pain (NRS 1/10) after tooth-clenching. Similar findings, using the same 
tooth-clenching model, induced low levels of pain intensity in healthy participants (Dawson 
et al., 2013). In another study were experimental tooth-grinding was used, with a maximal 
voluntary occlusal force of 50 % for 9 sessions during 45 minutes, report significantly 
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increased soreness, but not pain, in the masseter muscle immediately after the experiment in 
ten healthy male participants (Arima et al., 2000). Other studies using different experimental 
tooth-grinding and tooth-clenching models show a similar pattern, were low levels of pain are 
induced in healthy participants immediately after the exercise and quickly disappears 
(Bowley and Gale, 1987; Scott and Lundeen, 1980; Svensson et al., 2001a).  
 
Overall, the differences on pain characteristics between the experimental pain models used in 
this thesis, suggest that not all experimental pain models are adequate to use in healthy 
participants when studying chronic human muscle pain. 
 
Effect on pain variables of granisetron  
 
Results on pain intensity after pre-treatment with granisetron or placebo, followed by acidic 
saline or HS injections respectively are shown in Figure 6. 
 
 
Figure 6. Graph showing the mean (SD) peak pain intensity (VAS 0-100 mm) in the masseter 
muscle of healthy participants after pre-treatment with granisetron or placebo and 
experimentally induced muscle pain with acidic saline or HS injections. The pain intensity 
was significantly lower on the side pre-treated with granisetron compared to placebo, both 
after acidic saline (P < 0.05) and HS injections (P < 0.001). I = study I; II = study II. 
* = Significant differences between substances (granisetron and placebo). 
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The pain duration and pain area after pre-treatment with granisetron or placebo, followed by 
acidic saline or HS injections respectively are displayed in Figure 7.  
 
 
Figure 7. Graph showing the mean (SD) pain duration (sec) and painful area (au) in the 
masseter muscle of healthy participants after pre-treatment with granisetron or placebo and 
experimentally induced muscle pain with acidic saline or HS injections. The pain duration 
and pain area was significantly lower on the side pre-treated with granisetron compared to 
placebo, both after acidic saline (P < 0.05) and HS injections (P < 0.001). I = study I; II = 
study II. 
 * = Significant differences between substances (granisetron and placebo; P < 0.05).  
 
The second HS injection induced less pain than the first (P < 0.001) which indicates that an 
activation of the diffuse noxious inhibitory control (DNIC) occurred. Since pain was induced 
simultaneously at both sides, the effect was the same, thus did not influence the results. 
 
In accordance to previous studies, pre-treatment with granisetron reduced experimentally 
induced muscle pain (Christidis et al., 2008; Ernberg et al., 2000a), both by repeated acidic 
saline injections and HS injections. Several studies have shown a pain reducing effect of 5-
HT3-antagonist on other types of pain conditions such as neck pain, back pain and 
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fibromyalgia (Ettlin, 2004; Farber et al., 2001; Stratz and Muller, 2004). However, the pain 
reducing effect was greater after the HS injection compared to the acidic saline injections. 
Pre-treatment with granisetron caused 66 % lower pain than the control side after a HS 
injection, compared to 42 % lower pain after acidic saline injections. One explanation might 
be that the acidic saline injections caused lower levels of pain compared to the HS injection, 
and thus the possibility to reduce the pain intensity is less. Nevertheless, the pain intensity 
after acidic saline injections and granisetron was reduced to the same magnitude as after the 
HS injection and granisetron (Figure 7).  
 
The variance in the pain reducing effect of granisetron and other 5-HT3- antagonists, has also 
been shown in other studies (Christidis et al., 2007; Ernberg et al., 2000a; Muller and Stratz, 
2004; Stratz et al., 2004). The reasons for this might be due to the usage of different 5-HT3- 
antagonists, since granisetron has higher affinity to the 5-HT3 receptor than tropisetron 
(Wong et al., 1995). Furthermore, the difference in methodology might also explain the 
variation in results. For example, two of the studies used repeated injections and were clinical 
(Ettlin, 2004; Stratz and Muller, 2004), whereas other studies were experimental and used a 
single injection of granisetron (Christidis et al., 2007; Voog et al., 2000). 
 
The evoked muscle pain by the different experimental pain models in this thesis may be due 
to a direct or an indirect activation of the nociceptors (Cairns et al., 2003). A direct activation 
through the sodium channels, and indirectly by the increased levels of algesic biomarkers 
(Cairns et al., 2003). The positive effect of granisetron on pain variables can therefore be 
discussed. Previous studies have shown that HS increased levels of glutamate (Tegeder et al., 
2002) and SP (Garland et al., 1995), and results from study III show an increased release of 5-
HT. This could indicate that the pain reducing effect might partially be due to a block of the 
5-HT3 receptors. However, there was also a positive effect on pain variables after acidic 
saline injections. In a previous microdialysis study, painful infusions with acidic saline 
showed no increased levels of algesic biomarkers such as 5-HT and glutamate in the masseter 
muscle (Ernberg et al., 2013). Hence, the pain reducing effect of granisetron might also be 
that the sodium channels are affected (Kuryshev et al., 2000).
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Changes in pressure pain threshold 
 
The PPT at baseline and after each experiment are shown in Figure 8. 
 
 
Figure 8. Graph showing the mean (SD) values of pressure pain thresholds (PPT; kPa) 
before and after each experiment. In studies III and IV (where microdialysis was performed), 
there was a significant difference before and after each experiment, in healthy controls (study 
III: P < 0.011) and in TMD myalgia patients (study IV: P < 0.024). I = study I; II = study II; 
III = study III; IV= study IV. TC = Tooth-clenching. 
* = Significant change compared to baseline (P < 0.05).  
 
After each experiment, PPT generally decreased but not consistently. In patients with TMD 
myalgia, the baseline values of PPT were lower than the control group (P < 0.001) and 
decreased significantly after tooth-clenching (P < 0.024). This was not surprising since pain 
on palpation is generally regarded as a key symptom of chronic muscle pain and has the 
strongest associations with TMD (Greenspan et al., 2011). 
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However, there are contradictory results regarding PPT after experimentally induced muscle 
pain. A few studies report reduced muscle PPT after HS injections while other studies report 
no effect (Graven-Nielsen, 2006). The various results regarding PPT in this thesis may be due 
to different modalities in pain stimulation by the experimental pain models, recruitment of the 
different groups and their previous pain experiences and the different methodology. For 
example, the pain intensity, pain duration and the pain spread varied after the experimental 
settings, which may have affected the outcome of the PPT. Yet, after a HS injection (studies 
II and III), PPT reduced significantly in study III but not in study II. Nevertheless, in study III, 
microdialysis was performed i.e. the trauma caused by the needle and probe inserted 
intramuscularly may have caused a sensitization in the muscle tissue, which possibly explains 
the reduced PPT.  
 
Further, PPT decreased significantly compared to baseline after microdialysis, in healthy 
participants (study III) and in TMD myalgia patients, but not in the control group (study IV). 
Also in another microdialysis study, it was shown that PPT was decreased significantly in 
TMD myalgia patients. (Dawson et al., 2014). One explanation for the differences could be 
that there were two different study populations that vary in their baseline PPT. Another 
explanation could be that the number of healthy participants in study IV was too small (n=10).  
 
The PPT did not increase after pre-treatment with granisetron (Figure 9). This was surprising 
since previous studies consistently have shown an increase of PPT after pre-treatment with 
granisetron, both locally and systemically (Christidis et al., 2008; Christidis et al., 2005; 
Christidis et al., 2007; Ernberg et al., 2003), although it looks like there was an increase of 
PPT in study I (P = 0.243). Yet, the different study populations such as their previous pain 
experiences, previous participation in other clinical studies (Sjolund and Persson, 2007) or 
different responses depending on female/male examiners must be taken into consideration 
(Levine and De Simone, 1991). 
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Figure 9. Graph showing the mean percentage differences of pressure pain thresholds (PPT; 
kPa) compared to baseline (0) and between substances, after pre-treatment with granisetron 
or placebo. There were no differences in the PPT between sides i.e. pre-treatment with 
granisetron did not affect the PPT. I = study I; II = study II. 
 
There were no significant changes in the PPT over the reference point (the right index finger) 
in any of the studies, suggesting that no central sensitization occurred. Allodynia is generally 
regarded a sign of central sensitization (Woolf, 2011), but the lowered PPT in the masseter 
muscle after each experiment may be due to peripheral sensitization. 
 
5-HT3 polymorphisms and pain variables 
 
In study II, participants were genotyped regarding the polymorphisms, rs1062613 and 
rs1176744 from the HTR3A/B genes. In the HTR3A gene, the distribution of the 
polymorphisms were as follows; 36 participants with the C/C genotype, 22 with C/C and 2 
with T/T. Since only two participants had the T/T genotype, it was combined with the 
heterozygous genotype C/T and compared to the homozygous genotype C/C. In the HTR3B 
gene, the distribution were; 23 participants with the genotype A/A, 26 with A/C and 11 with 
C/C.  
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There were no differences in pain intensity, pain duration, pain area or PPT between the 
different HTR3 alleles. Also, there were no differences between the HTR3 alleles in the 
treatment effect of granisetron on pain intensity, pain duration, pain area and PPT. Overall, 
the main results show no direct association between the polymorphisms of the HTR3A/B 
genes respectively and experimental induced muscle pain by HS injection or the effect of 
granisetron.  
 
A previous study showed that there are 358 genes thought to be involved in pain processing, 
but only a few have been associated with TMD namely; HTR2A, COMT, NR3C1, CAMK4, 
CHRM2, IFRD1, and GRK5 (Smith et al., 2011). Yet, none of the polymorphisms have 
shown an association with the risk of TMD onset, however several polymorphisms were 
associated with intermediate phenotypes shown to be predictive of TMD onset (Smith et al., 
2013). Other studies have reported an association with polymorphisms in the HTR3A/B 
genes in a few pain conditions and psychiatric disorders (Hammer et al., 2009; Kapeller et al., 
2008; Kilpatrick et al., 2011; Niesler et al., 2001; Yamada et al., 2006) and also healthy 
subjects with the SNP rs1176744, carrying the C genotype in the HTR3B gene showed an 
association to higher Pain Catastrophizing Scale scores. However, results from study II, show 
no association between the HTR3 genes and experimental muscle pain. 
 
Other studies have shown that polymorphisms in HTR3A/B genes, influence the effect of the 
5-HT3 antagonist and the antidepressant response of the serotonin selective reuptake inhibitor 
(SSRI) paroxetine, by serving as predictors (Kato et al., 2006; Niesler et al., 2008). However, 
results from study II showed no direct association between the polymorphisms and the 
efficacy of granisetron. Yet, the sample size was relatively small which may have affected the 
results. Nevertheless, there were not even tendencies to a difference between the pain 
variables or the effect of granisetron and polymorphisms, suggesting that the results reported 
might reflect the true circumstances.  
 
However, there are limited studies investigating the association between 5-HT 
polymorphisms and pain conditions and the effect of granisetron and various 
pharmaceuticals. Therefore, no further conclusions may be drawn. 
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Microdialysis and the levels of biomarkers 
 
In studies III and IV, intramuscular microdialysis in the masseter muscle was performed to 
sample muscle biomarkers and investigate if changed levels occurred after experimentally 
induced muscle pain. The microdialysis technique has been used in several studies in order to 
study the local in vivo biochemistry of different tissues (Ernberg et al., 1999; Gerdle et al., 
2008a; Gerdle et al., 2010; Rosendal et al., 2004b; Shah et al., 2005; Tegeder et al., 2002). 
 
Study III 
 
There were increased levels of 5-HT, glutamate and glycerol (P’s < 0.05) after a HS injection 
and there was a significant correlation between pain intensity and the levels of 5-HT and 
glycerol. Also, 5-HT, glutamate and glycerol changed significantly over time at the HS side 
(P < 0.05; Friedman test) but not at the control side. The other mediators lactate, pyruvate and 
glucose, did not differ over time or between sides (Figure 10). 
 
Figure 10. Graph showing the levels of biomarkers in the masseter muscle during the 
baseline (BL), experiment (Ex) and recovery (Rec). The biomarkers investigated were: 
serotonin (A), glutamate (B), glycerol (C), pyruvate (D), lactate (E) and glucose (F).  
* = Significant differences between substances (P < 0.05). 
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The results are in line with previous studies showing increased levels of 5-HT in patients with 
TMD compared to healthy controls (Ernberg et al., 1999; Ghafouri et al., 2010; Shah et al., 
2005). Also, a previous study showed that glutamate was released after a HS injection in the 
bicep muscle in healthy participants (Tegeder et al., 2002). Other studies reported no 
increased levels of 5-HT or glutamate in the masseter muscle after experimental tooth-
clenching and acidic saline injections (Dawson et al., 2013; Ernberg et al., 2013). The reason 
for the different outcomes may be due to various experimental pain model that was used i.e. 
since lower pain intensity was evoked by experimental tooth-clenching and acidic saline 
injections compared to HS injections. This indicates that HS, which already is regarded as a 
valid experimental pain model for myalgia, also seem to be valid due to the release of 5-HT 
and glutamate. 
 
There are a number of studies reporting increased levels of 5-HT and glutamate in trapezius 
and masseter myalgia with a positive correlation to muscle pain and tenderness (Castrillon et 
al., 2010; Ernberg et al., 1999; Flodgren et al., 2005; Ghafouri et al., 2010; Larsson et al., 
2008; Rosendal et al., 2004b). Although these studies were performed by the same research 
group following similar study protocols, one can consider the findings reliable. This, since 
another research group has used a similar study protocol in respect of the duration of 
microdialysis, the solution of dialysate, the perfusion rate as well as recovery (Stahle and 
Borg, 2000).  
 
The results from study III show a positive correlation between 5-HT and pain intensity which 
is in line with previous studies (Ernberg et al., 1999; Gerdle et al., 2008b), indicating that 5-
HT plays an important role in muscle pain. Also, patients with TMD and trapezius myalgia 
showed a positive correlation between glutamate and pain (Castrillon et al., 2010; Rosendal et 
al., 2004b), however no such correlation was found in study III. This might be due to 
differences between clinical pain in TMD myalgia patients and experimentally induced 
muscle pain in healthy participants. Furthermore, glycerol correlated negatively to pain 
intensity. Glycerol has been suggested to be a useful marker of muscle damage after surgery 
(Hillered et al., 1998). However, since there are limited knowledge on the relationship 
between glycerol and pain, no certain conclusions can be drawn. Further studies are needed to 
estimate any possible relationship between glycerol and pain. 
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The blood flow did not alter between sides or after a HS injection, which is in line with a 
previous study using an experimental tooth-clenching task (Dawson et al., 2013). However, 
since we changed the dialysate vials every 20th minute, changes in the blood flow might have 
occurred during shorter periods of time, thus not have been detected. Since no measurable 
changes in the blood flow could be detected in study III and in previous studies (Dawson et 
al., 2013, 2015), the blood flow was not analyzed in study IV. 
 
Furthermore, the questionnaires of psychological nature (STAI and PSS-14) indicate that the 
levels of anxiety and stress were within the normal range in both the men and women. A 
previous study suggest that the pain experience can be intensified by psychological aspects 
such as stress and anxiety (Melzack, 1980). However, no such interaction could be confirmed 
in this study.  
 
Study IV 
 
Several cytokines: IL-2, IL-4, IL-5, IL-10 and IFN-γ, could not be detected in a sufficient 
number of samples i.e. the LOD was below 50 %, therefore they were excluded from the 
statistical analysis, in line with previous study from our research group (Ernberg et al, 
personal communication). Another study has used similar approach but with less strict 
criteria (Chaturvedi et al., 2011).  
 
There were higher levels of the pro-, and anti-inflammatory cytokines IL-6, IL-7, IL-8 and 
IL-13 in TMD myalgia patients compared to healthy controls during the entire microdialysis. 
After tooth-clenching, the cytokine levels of IL-6, IL-7, IL-8, IL-13 and TNF increased in 
TMD myalgia patients and IL-6 and IL-8 in controls (Figure 11), but there were no 
significant differences between the groups. 
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Figure 11. Graph showing the cytokine levels (mean and SEM) in the masseter muscle 
during microdialysis (0-220 min) in 20 women with TMD myalgia and 20 pain-free healthy 
women. After baseline (120-140 min), a 20-minute tooth-clenching task (140-160 min) was 
performed, followed by one hour of rest. The cytokines investigated were: IL-1β, IL-6, IL-7, 
IL-8, IL-12, IL-13, TNF and GM-CFS. 
* = Significant differences between groups (P < 0.05). 
 
These finding are partly in line with other studies showing increased levels of IL-6 in the 
trapezius muscle in patients with WAD (Gerdle et al., 2008b) and IL-1β, IL-6, IL-8 and TNF 
in myofascial trapezius trigger points (Shah et al., 2008; Shah et al., 2005). Further, recent 
results showed that the lipopolysaccharide (LPS) stimulated monocytes from patients with 
TMD, show an enhanced production of IL-1β, TNF and IL-6 (King et al., 2016). This gives 
support to an involvement of peripheral mechanisms in chronic myalgia, and may implicate 
that patients with chronic pain constantly have their immune system switched on with higher 
levels of inflammatory mediators, leading to peripheral sensitization, which may drive the 
pain (Kidd and Urban, 2001). 
 
In plasma, the cytokine levels seem to differ between patients with localized TMD and 
patients with widespread pain and TMD (Kosek et al., 2015; Park and Chung, 2016; Slade et 
al., 2011b). Although, cytokines in plasma were not analyzed in this study, previous study 
report elevated plasma levels of IL-1β, IL-6, TNF and IL-10 in patients with localized TMD 
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(Park and Chung, 2016), whereas in patients with widespread pain and fibromyalgia, IL-8 
was higher (Kosek et al., 2015; Slade et al., 2011b) and IL-10 lower compared to controls 
(Torgrimson-Ojerio et al., 2014). The reason for the diverse outcome may be due to 
differences in the balance between pro- and anti-inflammatory cytokines between localized 
TMD and widespread pain (Slade et al., 2011b), suggesting a more central pro-inflammatory 
state in widespread pain than in localized pain. 
 
There were no significant differences in cytokine levels between patients and healthy controls 
after experimental tooth-clenching (160 min), although there was a tendency of higher levels 
of IL-8 in TMD myalgia patients in comparison to healthy controls (Mann-Whitney U-test; P 
= 0.071). A previous study partly supports this finding, were the levels of the pro-
inflammatory cytokine IL-8 and pain intensity increased after a brief working task, in 
fibromyalgia patients and healthy controls, although no significant difference between groups 
were found (Christidis et al., 2015a). Further, several studies report higher levels of IL-8 in 
cerebrospinal fluid and serum in patients with fibromyalgia compared to controls (Gur et al., 
2002; Kadetoff et al., 2012; Kosek et al., 2015). 
 
Pain and fatigue increased in response to tooth-clenching, in accordance to a previous study 
(Dawson et al., 2015), but did not correlate to cytokine levels (P > 0.102; rs < 0.384). This 
indicates that there is no direct cause-relation effect between pain and cytokine levels. Indeed, 
the increased pain might affect the release of other biomarkers (Ernberg et al., 1999; 
Rosendal et al., 2004b) or interactions between several other mechanisms (Svensson and 
Kumar, 2016). Yet, the balance and interaction between the pro- and anti-inflammatory 
cytokines as well as other inflammatory mediators needs to be considered before any further 
conclusions may be drawn. 
 
One might argue that the results from studies III and IV might have been affected by the 
insertion of the needle, causing a trauma in the muscle. A previous study showed that there is 
an increased release of 5-HT after an insertion of a microdialysis probe in the muscle 
(Ernberg et al., 1999). Nevertheless, studies have shown that lactate, pyruvate and 5-HT 
return to baseline levels within 1 hour after insertion of the microdialysis catheters (Ernberg 
et al., 1999; Rosendal et al., 2004a). In order to avoid a false positive result, a stabilization 
period of 2 hours was therefore set (Gerdle et al., 2010; Ghafouri et al., 2010; Rosendal et al., 
2004b). Also, one might claim whether the catheter was within the masseter muscle or not. 
However, when inserting the needle, a slight resistance is typically felt when penetrating the 
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muscle fascia, ensuring that the catheter was placed in the muscle in accordance to previous 
studies (Dawson et al., 2015; Ernberg et al., 2013). 
 
Another issue, could be the use of local anaesthesia (studies III and IV) before the insertion of 
the needle, which might have affected the interstitial muscle levels of biomarkers. In study 
III, a local topical anaesthetic cream (EMLA) was applied for 30 minutes on the masseter 
muscle at the injection site. And in study IV, a subcutaneous local injection with Lidocaine 
(Xylocaine 20 mg /ml) was given. However, a previous study has showed that topical 
anaesthetic cream (EMLA) applied for 30 minutes on the forearm, did not penetrate deeper 
than 2.5 mm (Bjerring and Arendt-Nielsen, 1990). Hence, the local anaesthesia most 
probably was insufficient to influence the levels of biomarkers in the underlying masseter 
muscle in study III. Regarding the injection with Lidocaine, the injections were given 
subcutaneously, with caution not to penetrate the underlying muscle. However, one cannot 
exclude the possibility that the masseter muscle might have been affected by the local 
injection, which must be taken under consideration. 
 
Sex differences  
 
In studies I-III, sex differences were analyzed regarding pain intensity, pain duration, pain 
area and PPT. Also, in studies I and II, sex differences regarding the pain reducing effect of 
granisetron were evaluated. Furthermore, sex differences concerning biomarkers and 5-HT3 
polymorphisms were reported in studies II and III.  
 
Experimentally induced muscle pain in the masseter muscles by acidic saline (study I) caused 
higher pain intensity, longer pain duration and larger pain area in women (P’s < 0.05). In 
study II, a HS injection caused higher pain intensity in women (P < 0.05), but the pain 
duration and pain area did not differ between sexes. However, in study III, a HS injection did 
not cause any sex differences in pain intensity, pain duration or pain area (Figure 12). 
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Figure 12. Graph showing the mean (SD) sex differences in pain intensity (0-100 mm), pain 
duration (sec) and painful area (au) after experimentally induced muscle pain in the masseter 
muscle in study I-III. I = study I; II = study II; III = study III. 
* = Significant differences between sexes (P < 0.05). 
 
In general, all experimental pain models caused more pain in women than men. This is in line 
with previous studies showing that women rate similar pain stimuli as more painful than men 
(Dao and LeResche, 2000), and are more sensitive to pain in different experimental settings 
such as chemical, electrical and thermal stimulus (Fillingim et al., 2009). For example, 
women experienced injections with glutamate and serotonin as more painful than men 
(Ernberg et al., 1999; Svensson et al., 2003) and reported larger pain spread after a HS 
injection in the masseter muscle (Christidis et al., 2008). In study III, there were no 
significant sex differences regarding pain intensity, pain duration or pain area which partly is 
supported by a previous study were no sex differences regarding pain intensity after a HS 
injection in the masseter muscle was reported (Christidis et al., 2008). However, although 
results from study III showed no significant differences, women in general reported higher 
pain intensity and larger pain area. 
 
In studies I and II, the masseter muscle was pre-treated with granisetron. Granisetron had a 
pain reducing effect on both sexes, with lower pain intensity and lesser pain area. However, 
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men had a better effect of granisetron on pain variables in general. In study I, women had 
significantly longer pain duration than men (P < 0.05), and in study II, women reported 
higher pain intensity, longer pain duration and larger pain area (P’s < 0.05) compared to men 
(Figure 13).  
 
 
Figure 13. Graph showing the mean (SD) sex differences in pain intensity (0-100 mm), pain 
duration (sec) and painful area (au) after pre-treatment with granisetron in the masseter 
muscle in study I and II. I = study I; II = study II. 
* = Significant differences between sexes (P < 0.05). 
 
Other studies report no sex difference in pain intensity, pain duration or pain area in response 
to pre-treatment with granisetron (Christidis et al., 2008; Ernberg et al., 2000a). However, 
studies also report diverging results on the effect of opioid analgesia. For example, women 
seem to respond better to the analgesic effect of both μ and κ- opioid agonists compared to 
men (Fillingim and Gear, 2004; Gear et al., 1996; Niesters et al., 2010). On the other hand, in 
an animal study the same opioids did not show any sex differences in opioid potency and 
efficacy (Lomas and Picker, 2005). Overall, clinical human studies report a better analgesic 
effect of μ and κ- opioid agonists in women than men, while human experimental studies 
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show a greater effect of the μ- opioid agonists (Fillingim and Gear, 2004). The reason for the 
diverse results has been suggested to be due to multiple factors such as; hormonal influences, 
psychological factors, drug response, genetic factors and the balance of analgesic/anti-
analgesic processes (Fillingim and Gear, 2004). 
 
In general, the PPT over the masseter muscle was higher in men compared to women at 
baseline, which is is in line with several studies (Christidis et al., 2005; Christidis et al., 2007; 
Ernberg et al., 1999; Ernberg et al., 2000b; Garcia et al., 2007; Okayasu et al., 2009). After 
experimentally induced muscle pain (studies I-III), the PPT did not differ significantly 
between sexes, although PPT seemed to be higher in men. Furthermore, there were no sex 
differences in PPT in response to granisetron (studies I, II). However, there are incongruent 
results regarding sex differences in response to granisetron in PPT. For example, one study 
showed that women had higher PPT than men after pre-treatment with granisetron and a 
painful injection with 5-HT (Ernberg et al., 2000a). Other studies report an increase of PPT in 
men after pre-treatment with granisetron (Christidis et al., 2008; Christidis et al., 2005). One 
reason for the diverse results might depend on if there was a female or male examiner 
(Levine and De Simone, 1991). Another explanation might be due to the study population i.e. 
their previous pain experiences and previous participation in other research studies (Sjolund 
and Persson, 2007). 
 
In study II, there were no sex differences in the allele distribution in any of the 5-HT3 
polymorphisms. However, there were some sex-to-gene interactions in pain variables. After 
HS injection, women with the C/C genotype (HTR3A), had a larger pain area (P = 0.015), 
and in the A/C genotype (HTR3B), women had higher pain intensity than men (P = 0.019). 
After pre-treatment with granisetron, women with the T allele (HTR3A) had less reduction of 
pain intensity (P = 0.041) and pain area (P = 0.005), and women homozygous with the C 
allele (HTR3B) had less reduction of pain intensity (P = 0.030), pain duration (P = 0.030) 
and pain area (P = 0.017) compared to men. 
 
A previous study have reported increased anxiety and amygdala responsiveness in IBS 
patients carrying the C/C genotype in the HTR3A gene (Kilpatrick et al., 2011). In another 
study, subjects with the C-allele in the HTR3B gene, were thought to be more sensitive to 
pain perception since a substitution of the nucleotides tyrosine to serine showed an increase 
response to 5-HT compared to tyrosine (tyr129) (Krzywkowski et al., 2008). These results 
suggest the possibility that women carrying the C-allele of the HTR3A/B genes could be at 
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higher risk for increased anxiety and pain since pain and depression share similar pathways 
(Delgado, 2004). Furthermore, in similarity with earlier studies showing a sex difference in 
the effect of analgesics such as opioids (Fillingim and Gear, 2004; Gear et al., 1996; Niesters 
et al., 2010), there were also sex differences in response to the effect of granisetron. Genetic 
factors might be one of many factors contribution to sex differences. 
 
Overall, the results show that women are more sensitive to different type of painful stimulus 
than men. Also, men responded better to the pain reducing effect of granisetron and had 
higher baseline PPT than women. The reason why women in general report the same painful 
stimuli as stronger than men can be discussed. Since pain is multifactorial, there are several 
factors thought to contribute to sex differences in pain response, for example biological, 
psychological and sociocultural factors. According to the well-recognized OPPERA study, 
the odds of developing TMD were reported three times higher in women compared to men, 
thus, viewed as a risk factor of TMD (Slade et al., 2011a). In another study, were sex 
differences was reported regarding the onset of TMD, more women than men developed 
TMD pain in their early adolescent, suggesting that sex hormones play an important role in 
the development of orofacial pain (TMD) (Nilsson et al., 2005). Furthermore, the pain 
thresholds in the masseter muscle varied during different phases of the menstrual cycle 
(Drobek et al., 2002). Also, psychological factors are suggested to affect the outcome. 
Previous study show that men report more anxiety than women, and that there is an 
association between high levels of anxiety and low pain thresholds (Frot et al., 2004).  
 
In study III, the biomarker levels of 5-HT, glutamate, lactate, pyruvate, glucose or glycerol, 
did not differ between sexes at any time point. One could speculate if this result could be due 
to the small sample size. Yet, there were not even tendencies of sex differences in the release 
of biomarkers, suggesting that it might be a true finding. Since there are only a few 
microdialysis studies that report sex differences when examining the intramuscular levels of 
biomarkers, these findings cannot be confirmed. Hence, further studies that include both 
sexes are needed in order to compare biomarker levels between sexes.  
 
Furthermore, there were no sex differences in the levels of anxiety (STAI) or stress (PSS-14). 
Previous studies have shown that more women than men are diagnosed with anxiety and 
mood disorders (Gater et al., 1998), and that psychological disorders can affect pain 
(Delgado, 2004). However, since we investigated a relatively small, young and healthy 
population group, it was not surprising that no sex difference was found. 
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GENERAL DISCUSSION 
 
The riddle behind the complex mechanisms of chronic pain still remains. There are many 
pieces that needs to be put together to get a comprehensive view, for example both peripheral 
and central mechanisms most likely interact in the etiology of chronic pain (Scholz and 
Woolf, 2002). In this thesis however, the focus has been to highlight and investigate 
peripheral mechanisms that may contribute to the underlying factors behind the 
pathophysiology of TMD myalgia. Since it has been suggested that mechanical overloading 
and disturbed local blood flow may lead to local ischemia and peripheral release of algesic 
substances (“inflammatory soup”), which may induce and maintain muscle pain and thus be 
of importance for the pathogenesis of chronic myalgia (Mense, 1993, 2003), the emphasis has 
been on biomarkers in chronic and experimental human muscle pain.  
 
The main findings were that granisetron had a pain reducing effect on experimentally induced 
muscle pain, with a generally better effect in men, but the 5-HT3 polymorphisms did not 
influence the pain variables or the efficacy of granisetron in healthy individuals. Yet, there 
were sex differences in pain response and the pain reducing effect which seem to be 
influenced by the 5-HT3 polymorphisms. Furthermore, experimentally evoked pain in the 
masseter muscle caused increased levels of the biomarkers; 5-HT, glutamate and glycerol in 
healthy pain-free participants, and 5-HT was positively correlation to pain intensity. Also, 
patients with TMD myalgia had constantly higher levels of pro- and anti-inflammatory 
cytokines compared to healthy controls, and several cytokines increased in response to tooth-
clenching. However, there was no correlation between the cytokine levels and pain or fatigue. 
 
Experimental pain models 
 
The use of experimental pain models aim to mimic the clinical situation in order to study the 
pathophysiology behind chronic pain (Arendt-Nielsen et al., 2007). Experimental pain 
models should be standardized (Graven-Nielsen and Arendt-Nielsen, 2003; Graven-Nielsen 
et al., 2001; Le Bars et al., 2001). A standardized pain model reduces the variability in 
experimentally induced pain and increases reliability. Thus, a standardized pain model has a 
high validity if it shows similar results to the pain it will imitate (Arendt-Nielsen et al., 2007). 
Three experimental pain models, both endogenous and exogenous methods, have been used 
in this thesis namely; repeated acidic saline injections, HS injections and static tooth-
clenching. 
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The results show that not all of the experimental pain models used in this thesis are ideal as 
models for chronic orofacial muscle pain, since there was a variability in pain variables. 
Repeated acidic saline injections caused low levels of muscle pain with no pain referral or 
mechanical hyperalgesia, and tooth-clenching induced low levels of muscle pain only in one 
single healthy participant, and was thus, inadequate to use on pain-free participants. HS on 
the other hand, induced high levels of muscle pain with pain referral. Nevertheless, the pain 
induced was more similar to acute pain. 
 
Another criterion that may increase the validity of an experimental pain model, is to 
investigate whether the induced pain affects the levels of biomarkers in the tissue. 
Since patients with trapezius and masseter myalgia had increased levels of biomarkers 
(Ernberg et al., 1999; Ghafouri et al., 2010), it is reasonable to expect that experimental pain 
would show a similar pattern. A previous study showed that infusions with acidic saline into 
the masseter muscle did not cause the release of the biomarkers 5-HT and glutamate (Ernberg 
et al., 2013) in healthy participants, neither did static tooth-clenching, using the same 
methodology as in this thesis, cause higher masseter muscle levels of 5-HT and glutamate 
(Dawson et al., 2015). However, HS injection into the masseter muscle caused a significant 
release of 5-HT, glutamate and glycerol, and the level of 5-HT correlated to the pain intensity 
evoked (study III). This increases the validity of the HS injection as an adequate experimental 
pain model. 
 
5-HT3 polymorphisms and the efficacy of granisetron 
 
In concordance to previous studies, experimentally induced muscle pain could be blocked by 
a single injection of the 5-HT3-antagonist granisetron in studies I and II (Christidis et al., 
2008; Ernberg et al., 2000a). Other 5-HT3 receptor antagonists such as tropisetron and 
ondasetron also show a positive effect on clinical muscle pain conditions (Stratz et al., 2002; 
Stratz and Muller, 2004). The pain reducing effect of granisetron may not only be due to the 
blocking of the 5-HT3 receptors, but also by the interaction with other substances in the 
chemical milieu. For example, one study showed that tropisetron inhibits PGE2 (Seide et al., 
2004) which have an immunomodulatory function on cytokines (Schneider et al., 2004). 
Also, another explanation to the pain reducing effect by the 5-HT3 receptor antagonist may be 
that they affect sodium channels. The sodium channels are known to participate in peripheral 
pain and play a role in inflammatory pain (Cairns, 2009). Furthermore, another speculation 
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has been that polymorphisms in the serotonergic system may be involved in the 
pathophysiology of chronic muscle pain (Smith et al., 2011) and contribute to the analgesic 
effect of the 5-HT3 antagonist granisetron. However, the pain reducing effect does not seem 
to be associated with the 5-HT3 polymorphisms investigated in this thesis (study II), at least 
not experimentally induced muscle pain. Yet, there were sex differences in pain response, 
which nonetheless partly seem to be attributed to the 5-HT3 polymorphisms investigated. A 
previous study showed that a combination of six polymorphisms was associated with greater 
odds of TMD (Slade et al., 2013). Therefore, the possibility that 5-HT polymorphisms could 
influence, predict or be a risk factor in developing chronic pain disorders such as chronic 
TMD myalgia cannot be excluded. Perhaps, several 5-HT polymorphisms systematically 
needs to be explored in further studies before any further conclusions can be drawn.  
 
Biomarkers 
 
Biomarkers, seem to play a role in biological processes such as pain modulation (Ptolemy 
and Rifai, 2010). Previous studies where the levels of biomarkers have been investigated, 
using the microdialysis technique, have shown that there are higher levels of biomarkers in 
different chronic myalgia conditions compared to healthy controls. For example, in patients 
with chronic trapezius myalgia, increased interstitial levels of 5-HT, glutamate, pyruvate and 
lactate were reported (Ghafouri et al., 2010; Larsson et al., 2008; Rosendal et al., 2004b) and 
5-HT and glutamate correlated to pain (Gerdle et al., 2008b; Rosendal et al., 2004b). In other 
studies, increased masseter levels of 5-HT and glutamate were reported in patients with TMD 
myalgia (Castrillon et al., 2010; Ernberg et al., 1999) and 5-HT correlated to pain intensity 
(Ernberg et al., 1999). Furthermore, in study IV, the levels of pro- and anti-inflammatory 
cytokines were constantly higher in TMD myalgia patients compared to pain-free controls. 
 
The higher levels of biomarkers in patients with chronic muscle pain compared to healthy 
controls, may support a previous suggestion that patients constantly have their immune 
system turned on (Kidd and Urban, 2001), supporting the hypothesis that peripheral 
mechanisms could be involved in the pathophysiology of chronic muscle pain. This 
imbalance of biomarkers, might trigger an inflammatory response, leading to peripheral 
sensitization that may in turn induce or maintain pain (Kidd and Urban, 2001). However, in 
study IV, there were also increased levels of anti-inflammatory cytokines, suggesting that 
they are produced in order to counterbalance this effect. Yet, not to a sufficient degree which 
might be due to a blunt response (King et al., 2016).  
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Nevertheless, the cytokine levels might have been affected by the insertion of the catheter 
causing a trauma in the muscle. Other studies have shown that the levels of 5-HT, lactate and 
pyruvate return to baseline within an hour after the insertion (Ernberg et al., 1999; Rosendal 
et al., 2004a), but it might possibly be different in regards to cytokines. A previous animal 
study showed that the plasma levels of cytokines in mice were elevated for 24 hours after 
skin damage compared to sham animals (Catania et al., 1999), and in a human study the 
cytokine levels were increased for 6 hours after the insertion of the microdialysis catheter  
into the vastus lateralis muscle in healthy male participants (Carson et al., 2015). Therefore, 
the stabilization period may be longer in patients with TMD myalgia compared to healthy 
controls which might have influenced the results.  
 
The levels of cytokines did not correlate to the pain or fatigue evoked by the experimental 
tooth-clenching task, indicating that no direct cause-relation effect between cytokine levels 
and pain or fatigue can be confirmed. One explanation might be that other biomarkers are 
released in response to the inflammatory cascade, and involved in pain modulation (Ernberg 
et al., 1999; Rosendal et al., 2004b). Another reason could be that the interaction between 
several risk factors such as; pain intensity, trauma/overloading, psychological, genetics, sleep, 
comorbidities, demographics and lifestyle, could be combined in various ways and be 
categorized into low, moderate and high risk (Svensson and Kumar, 2016). Also, other 
mechanisms such as central sensitization might be involved in pain modulation (Kidd and 
Urban, 2001).  
 
Furthermore, in patients with fibromyalgia or TMD with chronic widespread pain, there were 
higher plasma levels of pro-inflammatory cytokines (Kadetoff et al., 2012; Kosek et al., 2015; 
Slade et al., 2011b) and lower levels of an anti-inflammatory cytokine compared to healthy 
controls (Kadetoff et al., 2012). On the other hand, in patients with a more localized TMD, 
there were elevated levels of both pro- and anti-inflammatory cytokines (Park and Chung, 
2016), suggesting that there is a difference in the biomarker balance between chronic 
widespread pain and localized muscle pain (Slade et al., 2011b), indicating a more central 
pro-inflammatory state in widespread pain. This could imply that peripheral sensitization may 
be of greater importance in localized myalgia compared to widespread pain. 
 
Overall, the results from this thesis strengthen previous findings of peripheral involvement in 
chronic muscle pain (Castrillon et al., 2010; Ernberg et al., 1999; Gerdle et al., 2008b; 
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Ghafouri et al., 2010; Larsson et al., 2008; Rosendal et al., 2004b) since patients with 
masseter myalgia had elevated levels of biomarkers. This indicates that muscle inflammation 
could be involved in the pathophysiology of chronic masseter muscle pain. Still, a correlation 
between the levels of biomarkers and pain could not be confirmed. Therefore, other 
peripheral mediators and mechanisms, such as central sensitization might also be involved in 
the pathophysiology of chronic muscle pain. 
 
Methodological considerations 
Genotyping 
 
A limitation that needs to be addressed was that the genotyping of the 5-HT3 polymorphisms 
was performed after the experiment (study II), leading to uneven sized groups of participants 
with different genotypes, which complicated the statistical comparisons. Since only two 
participants had the genotype T/T (HTR3A), they were combined with the C/T group and 
compared to the homozygous C/C group, in line with a previous study (Kilpatrick et al., 
2011). In order to avoid this in future studies, genotyping could preferably be performed 
beforehand, in accordance to a previous study (Horjales-Araujo et al., 2013). Furthermore, 
another factor that can be taken under consideration, is to have a larger study population, 
which will improve the power of the statistical analyzes. 
 
Microdialysis 
 
A strength was that 13 cytokines, both pro- and anti-inflammatory were analyzed in one 
panel so that differences in their pattern during the microdialysis could be compared. Even 
though several cytokines were under LOD and had to be excluded, the most common 
cytokines could still be detected. There are a number of factors that can affect the dialysate 
levels namely; a) the flow-rate b) the diffusion-rate through the tissue c) the area and weight 
cut-off of the dialysis membrane, and d) the composition of the perfusate (Gerdle et al., 
2014). In future studies, the composition of the perfusate could be modified, maybe by adding 
a colloid to the ringer-solution, and thus perhaps detect more cytokines (Helmy et al., 2009). 
Furthermore, most microdialysis studies are performed in women, due to the higher 
prevalence of chronic myalgia conditions in women. Hence, in study IV, only women were 
included. In future studies men could also be included to be able to compare mediator levels 
between sexes.  
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Phase of the menstrual cycle 
 
One factor that can be view as a limitation was that the phase of the menstrual cycle and the 
use of contraceptives were not taken into consideration. A previous study show that pain 
intensity varies during the menstrual cycle due to the levels of hormones (LeResche et al., 
2003). Another study however, showed that the influence of the estrogen levels are 
contradictory (Warren and Fried, 2001), and most likely women participated in this project 
were in difference phases of the menstrual cycle, therefore, this aspect should merely have 
very limited or no impact on the results. However, this aspect probably has no major  
importance since it has been shown that the intra-individual variability in pain response is 
greater than the influence of estrogen (Sherman and Leresche, 2006). 
 
Hypotheses addressed 
 
The following hypotheses were addressed in this thesis; 
 
Study I:  
The hypotheses in study I were that 1) muscle pain induced by two repeated acidic saline 
injections into the masseter muscle of healthy volunteers can be blocked by the 5-HT3 
antagonist granisetron and 2) the pain-reducing effect by granisetron is better in men than in 
women. 
 
The results support the first hypothesis since muscle pain induced by two repeated acidic 
saline injections into the masseter muscle of healthy participants were blocked by the 5-HT3 
antagonist granisetron. However, results did not support the second hypothesis since the pain 
reducing effect by granisetron on peak pain and pain area was significant for both sexes, and 
the effect on pain duration was significant only in women. 
 
Study II: 
The hypotheses in study II were that 1) polymorphisms in the serotonergic system are of 
importance for pain transmission and for the efficacy of the 5-HT3 antagonist granisetron in 
experimentally induced muscle pain and 2) there are sex differences due to specific 
HTR3A/B genotypes in pain responses after experimentally evoked muscle pain and the 
analgesic effects of granisetron.  
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The results could not confirm the first hypothesis since results show that the 5-HT3 
polymorphisms did not seem to directly influence pain perception or the efficacy of 
granisetron for the group as a whole. However, results may support the second hypothesis, 
since there were some sex-to-gene interactions in pain response and in the effect of 
granisetron.  
 
Study III:  
The hypotheses in study III were that 1) muscle pain induced by HS in the masseter muscle 
causes a significant release of 5-HT, glutamate, lactate, pyruvate, glucose and glycerol and 2) 
the release of these muscle biomarkers are higher in women than in men.  
 
The results partly support the first hypothesis, since there were increased levels of 5-HT, 
glutamate and glycerol after a HS injection and a significant correlation between pain 
intensity and the levels of 5-HT and glycerol. However, results did not support the second 
hypothesis, since there were no sex differences in biomarkers after HS injection. 
 
Study IV: 
The hypotheses in study IV were that 1) the levels of pro- and anti-inflammatory cytokines 
are significantly higher in patients with TMD myalgia both at rest and after a repetitive tooth-
clenching task and 2) the release of cytokines are correlated with pain intensity and fatigue. 
 
The results partly support the first hypothesis since TMD myalgia patients had significantly 
higher levels of the pro- and anti-inflammatory cytokines IL-6, IL-7, IL-8 and IL-13 during 
the entire microdialysis compared to healthy controls. After tooth-clenching, the pro- and 
anti-inflammatory cytokines IL-6, IL-7, IL-8, IL-13 and TNF increased in TMD myalgia 
patients and IL-6 and IL-8 in healthy controls, but without any differences between the 
groups. Further, the results did no confirm the second hypothesis since there was no 
correlation between the cytokine levels and pain intensity and fatigue.  
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CONCLUSIONS 
 
The overall conclusions are that granisetron had a pain reducing effect on experimentally 
induced muscle pain, with a better effect in men in general. None of the 5-HT3 
polymorphisms appeared to influence the experimentally evoked muscle pain or the positive 
effect of granisetron.  
 
Further, the levels of the biomarkers 5-HT, glutamate and glycerol increased after 
experimentally induced muscle pain in the masticatory muscles. In addition, TMD myalgia 
patients had higher levels of the pro- and anti-inflammatory cytokines IL-6, IL-7, IL-8 and 
IL-13 compared to healthy controls. After tooth-clenching, the levels of IL-6, IL-7, IL-8, IL-
13 and TNF increased in patients, and IL-6 and IL-8 increased in controls. 
 
Clinical implications and future research 
 
Since the main aim of this thesis has been to focus on peripheral mechanisms behind chronic 
muscle pain, hence basic science, no direct clinical implication may be drawn. Nevertheless, 
basic science is essential in order to increase our understanding and broaden our knowledge 
with the purpose to improve the clinical approach, diagnostics and treatments.  
 
Our findings have highlighted the importance of the serotonergic system and its effect on 
pain variables and sex differences. Future studies are needed to systemically explore several 
5-HT polymorphisms in patients with chronic myalgia in order to better understand if and 
how they influence pain perception. Also, our results have shown that experimental pain 
causes increased levels of some peripheral biomarkers, but also that TMD myalgia patients 
have higher levels of some biomarkers compared to healthy controls, suggesting that chronic 
myalgia may be driven or maintained by muscle inflammation. However, more studies are 
needed to further explore other peripheral biomarkers and mechanisms such as central 
sensitization.  
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Studier har visat att en stor del av den svenska befolkningen lider av kronisk muskelsmärta. 
Omkring 40 % har smärtan lokaliserad till ansiktet och käkarna. En majoritet av dessa 
personer är kvinnor. Förutom det individuella lidandet är det ett stort problem för samhället 
med ökad sjukfrånvaro och sjukvårdskostnader som följd. Än så länge är inte orsakerna och 
mekanismerna som ligger bakom långvarig muskelsmärta fullständigt utredda. Vi vet inte 
heller varför kvinnor drabbas i högre utsträckning än män. Ökad kunskap om mekanismerna 
och orsakerna bakom denna muskelsmärta kommer att hjälpa oss förbättra diagnostiken, och 
medverka till nya behandlingsmetoder. Detta kan i sin tur på sikt leda till minskat behov av 
sjukvårdsresurser och vårdkostnader och inte minst, leda till minskat lidande för den enskilda 
individen. 
 
Huvudsymptomen vid långvarig smärta lokaliserad till käkmusklerna och/eller käkleden är 
lokal smärta och ömhet s.k. myalgi, ofta förenat med nedsatt gapförmåga, huvudvärk och 
nackvärk. Olika teorier bakom långvarig muskelsmärta är att psykosociala faktorer i 
kombination med stressrelaterad tandgnissling och tandpressning (bruxism) är bidragande 
faktorer. Vid bruxism överbelastas musklerna med syrebrist till följd av otillräcklig 
blodcirkulation vilket bidrar till muskelinflammation. Vid en inflammation frisätts olika 
ämnen såsom serotonin (5-HT), glutamat och olika typer av cytokiner som förmodligen 
bidrar till smärtan genom att binda till särskilda mottagarmolekyler (receptorer). Det är inte 
osannolikt att liknande mekanismer även bidrar vid muskulära smärttillstånd i andra delar av 
kroppen. Sannolikt påverkas dessutom denna av stress- och könshormoner vilket skulle 
kunna vara en bidragande förklaring till att fler kvinnor än män drabbas av långvarig 
muskelsmärta. 
 
Tidigare forskning har visat att 5-HT är en viktig substans för smärtfortledning vid långvarig 
muskelsmärta och att läkemedel som blockerar 5-HT har smärthämmande effekter. Det är 
dock en stor skillnad i effekt mellan olika individer. En förklaring är att varianter i vissa 
gener påverkar smärtkänsligheten och kan bidra till skillnaden i effekt av dessa läkemedel. På 
senare år har genetiska faktorer bakom olika sjukdomar fått stor uppmärksamhet. Även om 
ingen enskild gen har visats kunna orsaka långvarig muskelsmärta så har flera genetiska 
förändringar (polymorfismer) visats vara vanligare hos patienter med långvarig muskelsmärta 
än hos befolkningen i övrigt. Intressant är att polymorfismer i generna HTR3A/B har visat sig 
ha samband med depressionstillstånd. Eftersom långvarig muskelsmärta ofta är förenat med 
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depression skulle de också kunna påverka smärtkänsligheten och effekten av sådana 
läkemedel. 
 
Det övergripande syftet med denna avhandling är att öka kunskapen avseende patofysiologin 
(orsaksmekanismerna) vid käkmuskelsmärta, för att därigenom kunna förbättra diagnostiken, 
och upprätta ett mer rationellt omhändertagande. Avhandlingen syftar till att med hjälp av 
experimentella smärtmodeller undersöka förhållandet mellan smärtvariabler och frisättning 
av olika smärtframkallande ämnen (5-HT, glutamat, och cytokiner). Dessutom undersöktes 
vissa polymorfismer i generna HTR3A/B och deras påverkan på experimentellt framkallad 
muskelsmärta och effekten av behandling med ett serotoninblockerande läkemedel 
(granisetron). Friska frivilliga försökspersoner, på vilka man framkallar experimentell 
muskelsmärta, samt patienter med käkmuskelsmärta deltog i experimenten. 
 
I projektet användes olika experimentella smärtmodeller för att imitera/likna en långvarig 
muskelsmärta. I dagsläget finns ingen optimal experimentell smärtmodell som till fullo liknar 
ett kroniskt muskulärt smärttillstånd. Den smärtmodell som är mest validerad är injektion av 
hyperton koksalt, dock framkallar den en akut, skarp och kraftig smärta. Eftersom hyperton 
koksalt mer liknar en akut smärta skulle det vara fördelaktigt och eftersträvansvärt att ha en 
smärtmodell som efterliknar den kliniska långvariga smärtan mer korrekt. I detta projekt har 
vi använt oss av tre olika smärtmodeller: a) upprepade injektioner med surgjort koksalt b) 
injektion med hyperton koksalt och c) upprepad statisk tandpressningsövning.  
 
I den första studien använde vi oss av två upprepade injektioner av surgjort koksalt i 
käkmuskeln (massetermuskeln), då denna experimentella smärtmodell har visat sig vara 
framgångsrik i djurstudier där man lyckats efterlikna en mer långvarig smärta med en ökad 
smärtkänslighet 30 dagar efter den sista injektionen. I studie I undersökte vi därmed effekten 
av granisetron på den experimentellt framkallade muskelsmärtan samt om det förelåg några 
könsskillnader. Resultatet visade att granisetron hade en smärtreducerande effekt på den 
experimentellt framkallade muskelsmärtan genom upprepade injektioner med surgjort 
koksalt. Den surgjorda koksaltlösningen framkallade dock endast en mild lokal smärta i 
massetermuskeln utan någon ökad smärtkänslighet efter injektionerna. Trots att man i andra 
studier har försökt att modifiera smärtmodellen genom att öka injektionsvolymen samt 
använda sig av en buffrad surgjord koksaltlösning, har den inte visat sig vara lika 
framgångsrik som i djurstudier. Därmed, bedömdes den inte som optimal att använda i de 
övriga studierna.  
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I studie II användes injektioner med hyperton koksalt i massetermuskeln för att framkalla 
smärta. Blodprover togs för att analysera DNA och därmed titta på vilken roll 
polymorfismerna (rs1062613, rs1176744) i generna HTR3A/B har i förhållande till 
framkallad muskelsmärta i massetermuskeln och vilken effekt dessa har på läkemedlet 
granisetron. Resultaten visade att ingen av dessa polymorfismer påverkade den 
experimentellt framkallade muskelsmärtan i massetermuskeln eller effekten av granisetron på 
smärtvariabler generellt i hela gruppen, men det fanns vissa könsskillnader i smärtvariablerna 
som förefaller vara påverkade av genotyper.  
 
I studie III användes återigen injektioner av hyperton koksalt i massetermuskeln för att 
framkalla smärta och undersöka om det ledde till en frisättning av vissa biomarkörer (5-HT, 
glutamat, laktat, pyruvat, glukos och glycerol), och om det fanns några könsskillnader i detta 
avseende. Vi använde oss av en så kallas mikrodialysteknik (teknik för att separera små 
molekyler från stora i en vätska med hjälp av diffusion), för att analysera vilka ämnen som 
frisätts i massetermuskeln vid smärta. Denna teknik användes också i studie IV. Resultaten 
visade att 5-HT, glutamat och glycerol ökade efter en smärtsam injektion med hyperton 
koksalt i massetermuskeln, men utan några könsskillnader. Eftersom förhöjda nivåer av 5-HT 
och glutamat tidigare har rapporterats vid långvarig muskelsmärta, stärker detta validiteten 
för den experimentella smärtmodellen. 
 
I studie IV användes en 20-minuters statisk tandpressningsövning för att framkalla smärta i 
massetermuskeln. Vissa biomarkörer (cytokiner) undersöktes, dess svar på experimentell 
tandpressning och förhållande till smärta, trötthet och psykisk ohälsa hos patienter med 
långvarig muskelsmärta från massetermuskeln. Resultaten visade att nivåerna av vissa 
cytokiner (IL-6, IL-7, IL-8 och IL-13) är förhöjda i massetermuskeln hos patienter med 
långvarig muskelsmärta och att det ökade som svar på tandpressning. Tandpressningen ökade 
käkmuskelsmärtan och tröttheten, men utan någon korrelation till de ökade cytokinnivåerna. 
Den statiska tandpressningsövningen framkallade endast en låg smärta hos en enstaka frisk 
försöksperson, sålunda är denna smärtmodell kanske inte helt ideal för att använda på 
smärtfria försökspersoner. 
 
Sammanfattningsvis tyder resultaten från denna avhandling på att granisetron visade sig ha en 
smärtreducerande effekt på den experimentellt framkallade muskelsmärtan i 
massetermuskeln, men inga av de undersökta 5-HT3 polymorfismerna verkade påverka den 
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framkallade muskelsmärtan eller den positiva effekten av granisetron hos friska individer. 
Likväl fanns det könsskillnader i smärta och dess effekt på granisetron, vilka tycks vara 
påverkade av polymorfismerna. I och med detta, kan man inte helt utesluta att olika 
genvarianter i det serotonerga systemet kan påverka, förutsäga eller vara en riskfaktor för att 
utveckla kronisk muskelsmärta. Ytterligare forskning behövs dock för att systematiskt 
undersöka flera genvarianter för att dra några definitiva slutsatser. 
 
Ytterligare resultat visade att vissa biomarkörer ökar vid experimentellt framkallad 
muskelsmärta i massetermuskeln. Dessutom hade patienter med långvarig muskelsmärta i 
massetermusklerna en konstant förhöjd nivå av inflammationssubstanser (cytokiner) vilka 
ökade som svar på tandpressning. Detta indikerar att en eventuell muskelinflammation skulle 
kunna vara inblandad i patofysiologin bakom kronisk käkmuskelsmärta.  
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